2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 1/128

药智数据 https://db.yaozh.com

伊马替尼药物报告Imatinib Drug Report

药物英文名 Imatinib

药物中文名 伊马替尼

药物别名CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinibmesylate; QTI 571; Ruvise; STI 571

原研单位 NOVARTIS PHARMACEUTICALS CORP

全球最高状态 2001年批准上市

中国是否上市 是

      伊马替尼由Novartis研发，首先于2001年5月10日获美国食品药品管理局（FDA）批准上市，之后于2001年11月7日获欧洲药物管理局（EMA)批准上市，于2005年3月9日获日本医药品医疗器械综合机构（PMDA）批准上市。由诺华在美国上市销售(商品名:Gleevec)。伊马替尼是一种Bcr-Abl酪氨酸激酶抑制剂，能够抑制Bcr-Abl阳性细胞系及费城染色体阳性慢性粒细胞白血病的新鲜细胞的增殖和诱导其凋亡。伊马替尼也是血小板衍生生长因子（PDGF）、干细胞因子（SCF），c-Kit酪氨酸激酶抑制剂，从而抑制由PDGF和SCF介导的细胞活动。在体外，伊马替尼抑制活化的c-Kit突变表达的胃肠道间质瘤（GIST）细胞的增殖并诱导其死亡。该药用于治疗慢性粒细胞白血病（CML），胃肠道间质瘤（GIST）以及其他恶性肿瘤。Gleevec为口服薄膜衣片，每片含有100 mg或400 mg伊马替尼。推荐剂量为对于慢性期CML成年患者，每次400 mg，每日1次；对于急变期或加速期CML成年患者，每次600 mg，每日1次。

结构式

化学名称：α-(4-methyl-1-piperazinyl)-3'-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-p-toluidide

CAS登记号：152459-95-5

分子式：C29H31N7O

分子量：493.61

摘要信息

药物概述

API信息

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 2/128

ATC分类

L01XE01  抗肿瘤药和免疫机能调节药 > 抗肿瘤药 > 其它抗肿瘤药物 > 蛋白激酶抑制剂

作用靶点

Abl tyrosine kinase inhibitor; Bcr protein inhibitor; Kit tyrosine kinase inhibitor; PDGF receptorantagonist; Signal transduction inhibitor

申请号 商标名 活性成分 剂型/给药途径 批准时间 申请机构

021335

GLEEVEC IMATINIB MESYLATE CAPSULE;ORAL 2001-05-10 NOVARTIS

021588

GLEEVEC IMATINIB MESYLATE TABLET;ORAL 2003-04-18 NOVARTIS

078340

IMATINIB MESYLATE IMATINIB MESYLATE TABLET;ORAL 2015-12-03 SUN PHARMA GLOBAL

204285

IMATINIB MESYLATE IMATINIB MESYLATE TABLET;ORAL 2016-08-04 TEVA PHARMS USA

079179

IMATINIB MESYLATE IMATINIB MESYLATE TABLET;ORAL 2016-08-05 APOTEX INC

204644

IMATINIB MESYLATE IMATINIB MESYLATE TABLET;ORAL 2017-06-21 MYLAN PHARMS INC

编号 药品名称 活性成分 剂型 上市许可持有人 获批时间

EMEA/H/C/000406

Glivec imatinib Novartis Europharm Ltd 2001-11-07

EMEA/H/C/002585

Imatinib Teva imatinib Teva B.V. 2013-01-08

EMEA/H/C/002594

Imatinib Actavis imatinib Actavis Group PTC ehf 2013-04-17

EMEA/H/C/002681

Imatinib Accord imatinib Accord Healthcare Ltd 2013-07-01

药理作用

美国上市情况(6条)

欧盟上市情况(31条) 隐藏

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 3/128

编号 药品名称 活性成分 剂型 上市许可持有人 获批时间

EMEA/H/C/002692

Imatinib medac imatinib Medac 2013-09-25

NL/H/255

5/Imatinibe Farmia

imatinib400 mg

Filmcoated

tablet

PharOs Generics Ltd 2012-11-14

UK/H/641

2/Imatinibe Zentiva

imatinib400 mg

Filmcoated

tablet

Zentiva a.s - Praag - 102 37 - Tsjechië 2012-11-14

RO/H/0137/

Imatiinib 400 mghard capsules

imatinib400 mg

Capsule,

hard

Egis Pharmaceuticals PLC FormerUK/H/4677/002/DC

2013-02-04

RO/H/0137/

Imatiinib 100 mghard capsules

imatinib100 mg

Capsule,

hard

Egis Pharmaceuticals PLC formerUK/H/4677/001/DC

2013-02-04

UK/H/467

6/

NIBIX 400 mg hardcapsules

imatinib400 mg

Capsule,

hardAdamed Sp. 2013-02-04

UK/H/467

6/

NIBIX 100 mg hardcapsules

imatinib100 mg

Capsule,

hardAdamed Sp. 2013-02-04

SE/H/129

5/Imatinib Grindeks

imatinib100 mg

Capsule,

hardAS GRINDEKS, Latvia 2013-09-23

NL/H/272

5/

Imatinib Apotex400 mg

imatinib400 mg

Filmcoated

tablet

Apotex Europe BV 2013-11-26

SE/H/131

0/Imatinib Mylan

imatinib100 mg

Filmcoated

tablet

Mylan AB Sweden 2014-07-24

SE/H/131

0/Imatinib Mylan

imatinib400 mg

Filmcoated

tablet

Mylan AB Sweden 2014-07-24

NL/H/298

7/

Imatinib Hetero100 mg filmcoated

tablets

imatinib100 mg

Filmcoated

tablet

Hetero Europe S.L. Viladecans Business Park,Edificio Brazil, Catalunya 83-85 08840

Viladecans Barcelona Spain2014-08-21

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 4/128

编号 药品名称 活性成分 剂型 上市许可持有人 获批时间

NL/H/298

7/

Imatinib Hetero400 mg filmcoated

tablets

imatinib400 mg

Filmcoated

tablet

Hetero Europe S.L. Viladecans Business Park,Edificio Brazil, Catalunya 83-85 08840

Viladecans Barcelona Spain2014-08-21

NL/H/325

2/

Imatinib 100 mgfilm-coated tablets

imatinib100 mg

Film-

coated

tablet

Intrapharm Laboratories Limited TheCourtyard Barns, Choke Lane, Cookham Dean,

Maidenhead, Berkshire SL6 6PT UnitedKingdom

2015-06-19

NL/H/325

2/

Imatinib 400 mgfilm-coated tablets

imatinib400 mg

Film-

coated

tablet

Intrapharm Laboratories Limited TheCourtyard Barns, Choke Lane, Cookham Dean,

Maidenhead, Berkshire SL6 6PT UnitedKingdom

2015-06-19

NL/H/321

0/

Imatinib AccordHealthcare 100 mgfilm-coated tablets

imatinib100 mg

Film-

coated

tablet

Accord Healthcare Limited Sage house, 319Pinner Road, North Harrow, Middlesex HA1

4HF United Kingdom2015-06-19

NL/H/321

0/

Imatinib AccordHealthcare 400 mgfilm-coated tablets

imatinib400 mg

Film-

coated

tablet

Accord Healthcare Limited Sage house, 319Pinner Road, North Harrow, Middlesex HA1

4HF United Kingdom2015-06-19

UK/H/586

0/

Imatinib 400mgFilm-Coated

Tablets

imatinib400 mg

Filmcoated

tablet

Wockhardt UK Ltd, Ash Road North, Wrexham,LL13 9UF

2015-07-17

UK/H/586

0/

Imatinib 100mgFilm-Coated

Tablets

imatinib100 mg

Filmcoated

tablet

Wockhardt UK Ltd, Ash Road North, Wrexham,LL13 9UF

2015-07-17

NL/H/347

0/Imatinib Aenorasis

imatinib400 mg

Film-

coated

tablet

AENORASIS S.A. 17 Trapezountos & A.Papandreou st, Melissia 15127 Greece

2015-09-29

NL/H/347

0/Imatinib Aenorasis

imatinib100 mg

Film-

coated

tablet

AENORASIS S.A. 17 Trapezountos & A.Papandreou st, Melissia 15127 Greece

2015-09-29

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 5/128

编号 药品名称 活性成分 剂型 上市许可持有人 获批时间

NL/H/331

8/

Imatinib Sandoz400 mg

imatinib400 mg

Film-

coated

tablet

Sandoz B. V. Veluwezoom 22, 1327 AH AlmereP.O. box 10332, 1301 AH Almere The

Netherlands2015-10-14

NL/H/331

9/

Imatinib Sandoz400 mg

imatinib400 mg

Film-

coated

tablet

Sandoz B. V. Veluwezoom 22, 1327 AH AlmereP.O. box 10332, 1301 AH Almere The

Netherlands2015-10-14

NL/H/331

9/

Imatinib Sandoz100 mg

imatinib100 mg

Film-

coated

tablet

Sandoz B. V. Veluwezoom 22, 1327 AH AlmereP.O. box 10332, 1301 AH Almere The

Netherlands2015-10-14

NL/H/331

8/

Imatinib Sandoz100 mg

imatinib100 mg

Film-

coated

tablet

Sandoz B. V. Veluwezoom 22, 1327 AH AlmereP.O. box 10332, 1301 AH Almere The

Netherlands2015-10-14

DE/H/406

9/

Imatinib beta 400mg

imatinib477.88

mg

Filmcoated

tablet

betapharm Arzneimittel GmbH Kobelweg 95D-86156 Augsburg Germany

2016-06-15

DE/H/406

9/

Imatinib beta 100mg

imatinib119.47

mg

Filmcoated

tablet

betapharm Arzneimittel GmbH Kobelweg 95D-86156 Augsburg Germany

2016-06-15

药品名称 批准文号 药品规格 生产厂商 国产厂家数量 是否医保

甲磺酸伊马替尼

国药准字H20130074

---- 连云港润众制药有限公司 3

甲磺酸伊马替尼胶囊

国药准字H20133198

100mg(按C29H31N7O计算)

正大天晴药业集团股份有限公司

1

甲磺酸伊马替尼片

国药准字H20133200

0.1g(以C29H31N7O计)

江苏豪森药业集团有限公司 2

甲磺酸伊马替尼

国药准字H20130075

---- 江苏豪森药业集团有限公司 3

甲磺酸伊马替尼胶囊

国药准字H20133199

50mg(按C29H31N7O计算)

正大天晴药业集团股份有限公司

1

中国上市情况(10条)

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 6/128

药品名称 批准文号 药品规格 生产厂商 国产厂家数量 是否医保

甲磺酸伊马替尼片

国药准字H20143340

0.1g(按C29H31N7O计)

石药集团欧意药业有限公司 2

甲磺酸伊马替尼

国药准字H20140115

---- 石药集团欧意药业有限公司 3

甲磺酸伊马替尼片

H20150112 0.1g(按伊马替尼计)Novartis Pharma

Produktions GmbH德国进口

甲磺酸伊马替尼片

H20150298 0.4g(按伊马替尼计) Novartis Pharma Stein AG 瑞士进口

甲磺酸伊马替尼胶囊

H20150294 0.1g (按伊马替尼计) Novartis Pharma Stein AG 瑞士进口

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CXL00888STI571

胶囊新药 1

2001-01-05

香港诺华制药有限公司北京

代表处

在审批

CXL00887STI571

胶囊新药 1

2001-01-05

批准

A20010097甲磺酸伊

马替尼新药

2001-11-22

香港诺华制药有限公司北京

代表处

审批完毕 批准

B20020128甲磺酸伊马替尼胶

囊进口

2002-10-24

香港诺华制药有限公司北京

代表处

审批完毕 2003-03-19 批准

J0300342甲磺酸伊马替尼胶

囊补充申请

2003-04-08

香港诺华制药有限公司北京

代表处

审批完毕 2003-10-23 批准临床

J0401333甲磺酸伊马替尼胶

囊

进口再注册

2004-07-21

北京诺华制药有限

公司

制证完毕－已发批件

2005-01-06批准再注

册

J0400002甲磺酸伊马替尼片

进口 3.12004-08-

09

香港诺华制药有限公司北京

代表处

制证完毕－已发批件

2005-01-17 批准进口

J0400001甲磺酸伊马替尼片

进口 3.12004-08-

09

香港诺华制药有限公司北京

代表处

制证完毕－已发批件

2005-01-17 批准进口

J0402300甲磺酸伊马替尼胶

囊补充申请

2004-12-22

北京诺华制药有限

公司已发批件 2005-05-19 批准临床

中国注册申报情况(158条) 隐藏

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 7/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JYHB0500346

甲磺酸伊马替尼片

补充申请2005-05-

25

北京诺华制药有限

公司已发批件 2005-09-28 批准临床

JYHB0500347

甲磺酸伊马替尼片

补充申请2005-05-

25

北京诺华制药有限

公司已发件 2005-09-28 批准临床

JYHB0500780

甲磺酸伊马替尼胶

囊补充申请

2005-11-25

北京诺华制药有限

公司

制证结束待发送-未批准

2006-04-18 批准补充

JYHB0500807

甲磺酸伊马替尼片

补充申请2005-12-

07

北京诺华制药有限

公司

制证完毕－待发批件

2006-06-19 批准补充

JYHB0500808

甲磺酸伊马替尼片

补充申请2005-12-

07

北京诺华制药有限

公司

制证结束待发送-已批准

2006-06-19 批准补充

JYHB0600461

甲磺酸伊马替尼片

补充申请2006-09-

06

北京诺华制药有限

公司已发批件 2007-11-19 批准补充

JYHB0600462

甲磺酸伊马替尼片

补充申请2006-09-

06

北京诺华制药有限

公司已发批件 2007-11-19 批准补充

JXHL0700206

甲磺酸伊马替尼片

进口 3.42007-07-

25

北京诺华制药有限

公司

制证完毕－已发批件

2009-02-11 批准进口

JXHL0700207

甲磺酸伊马替尼片

进口 3.42007-07-

25

北京诺华制药有限

公司

制证完毕－已发批件

2009-02-11 批准进口

JYHB0700993

甲磺酸伊马替尼片

补充申请2007-09-

25

北京诺华制药有限

公司

制证完毕－已发批件

2008-04-11 不批准

JYHB0700992

甲磺酸伊马替尼片

补充申请2007-09-

25

北京诺华制药有限

公司

制证完毕－已发批件

2008-04-11 不批准

JYHB0701003

甲磺酸伊马替尼胶

囊补充申请

2007-09-25

北京诺华制药有限

公司

制证完毕－已发批件

2008-04-11 不批准

JYHB0701149

甲磺酸伊马替尼片

补充申请2007-11-

28

北京诺华制药有限

公司

制证完毕－已发批件

2008-05-23 批准补充

JYHB0701150

甲磺酸伊马替尼片

补充申请2007-11-

28

北京诺华制药有限

公司

制证完毕－已发批件

2008-05-23 批准补充

JXHL0800401

甲磺酸伊马替尼片

进口2008-12-

02

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-04-09 批准进口

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 8/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JXHL0800402

甲磺酸伊马替尼片

进口2008-12-

02

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-04-09 批准进口

JXHL0900090

甲磺酸伊马替尼片

进口2009-03-

26

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-05-24 批准进口

JXHL0900089

甲磺酸伊马替尼片

进口2009-03-

26

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-05-24 批准进口

JYHZ0900238

甲磺酸伊马替尼胶

囊

进口再注册

2009-07-09

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-04-22批准再注

册

JYHZ0900262

甲磺酸伊马替尼片

进口再注册

2009-07-16

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-04-27批准再注

册

JYHZ0900261

甲磺酸伊马替尼片

进口再注册

2009-07-21

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2010-04-27批准再注

册

JYHB1000793

甲磺酸伊马替尼胶

囊补充申请

2010-09-14

北京诺华制药有限

公司

制证完毕－已发批件

2011-02-14 批准补充

CXHS1000211

甲磺酸伊马替尼

新药 3.12010-10-

27

江苏正大天晴药业股份有限

公司

制证完毕－已发批件

2011-12-27 批准临床

CYHS1000855

甲磺酸伊马替尼胶

囊仿制 6

2011-02-22

江苏正大天晴药业股份有限

公司

制证完毕－已发批件

2011-12-22 批准临床

CYHS1000854

甲磺酸伊马替尼胶

囊仿制 6

2011-02-22

江苏正大天晴药业股份有限

公司

制证完毕－已发批件

2011-12-22 批准临床

CXHS1100035

甲磺酸伊马替尼

新药 3.12011-04-

26

江苏豪森医药集团连云港宏创医药有

限公司

制证完毕－已发批件

2011-11-15终止审批

程序

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 9/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CYHS1100172

甲磺酸伊马替尼片

仿制 62011-05-

16

江苏豪森药业股份有限公司

制证完毕－已发批件

2011-11-15终止审批

程序

CYHS1101059

甲磺酸伊马替尼片

仿制 62011-09-

20

江苏豪森药业股份有限公司

制证完毕－已发批件

2012-09-05 批准临床

CXHS1100191

甲磺酸伊马替尼

新药 3.12011-09-

20

江苏豪森医药集团连云港宏创医药有

限公司

制证完毕－已发批件

2012-08-28 批准临床

JYHB1100867

甲磺酸伊马替尼片

补充申请2011-10-

18

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2014-01-30 批准补充

JYHB1100866

甲磺酸伊马替尼胶

囊补充申请

2011-10-18

北京诺华制药有限

公司

制证完毕－已发批件

2014-01-22

JYHB1100868

甲磺酸伊马替尼片

补充申请2011-10-

18

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2014-01-30 批准补充

CXHS1100181

甲磺酸伊马替尼

新药 3.12011-11-

14

重庆福安药业（集团）股份有限公司

制证完毕－已发批件

2013-04-17 批准临床

CYHS1101033

甲磺酸伊马替尼胶

囊仿制 6

2011-11-23

重庆市庆余堂制药有限公司

制证完毕－已发批件

2013-04-23 批准临床

CYHS1101034

甲磺酸伊马替尼片

仿制 62011-11-

23

重庆市庆余堂制药有限公司

制证完毕－已发批件

2013-04-23 批准临床

CYHS1100884

甲磺酸伊马替尼片

仿制 62011-12-

05

石药集团中奇制药技术（石家庄）有

限公司

制证完毕－已发批件

2013-04-25 批准临床

CXHS1100158

甲磺酸伊马替尼

新药 3.12011-12-

05

石药集团中奇制药技术（石家庄）有

限公司

制证完毕－已发批件

2013-04-17 批准临床

JYHB1200234

甲磺酸伊马替尼胶

囊补充申请

2012-03-16

北京诺华制药有限

公司

制证完毕－已发批件

2013-01-15 批准补充

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 10/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JYHB1200235

甲磺酸伊马替尼片

补充申请2012-03-

16

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2013-01-17 批准补充

JYHB1200236

甲磺酸伊马替尼片

补充申请2012-03-

16

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2013-01-17 批准补充

CXHS1200063

甲磺酸伊马替尼

新药 3.12012-04-

20

南京先声东元制药有限公司

制证完毕－已发批件

2013-07-09 批准临床

CXHS1200083

甲磺酸伊马替尼

新药 3.12012-05-

14

齐鲁天和惠世制药有限公司

制证完毕－已发批件

2013-07-09 批准临床

CYHS1200412

甲磺酸伊马替尼片

仿制 62012-05-

21

齐鲁制药(海南)有限公司

制证完毕－已发批件

2013-07-09 批准临床

CYHS1200413

甲磺酸伊马替尼片

仿制 62012-05-

21

齐鲁制药(海南)有限公司

制证完毕－已发批件

2013-07-09 批准临床

JXHL1200168

甲磺酸伊马替尼片

进口2012-05-

22

PlivaCroatia

Ltd.

制证完毕－已发批件

2014-12-01 批准临床

JXHL1200167

甲磺酸伊马替尼片

进口2012-06-

13

PlivaCroatia

Ltd.

制证完毕－已发批件

2014-12-01 批准临床

CXHS1200122

甲磺酸伊马替尼

新药 3.12012-06-

19

连云港润众制药有

限公司

制证完毕－已发批件

2013-07-03 批准生产

CYHS1290061

甲磺酸伊马替尼胶

囊仿制 6

2012-06-19

江苏正大天晴药业股份有限

公司

制证完毕－已发批件

2013-07-03 批准生产

CYHS1290062

甲磺酸伊马替尼胶

囊仿制 6

2012-06-19

江苏正大天晴药业股份有限

公司

制证完毕－已发批件

2013-07-03 批准生产

CXHS1200087

甲磺酸伊马替尼

新药 3.12012-07-

06

浙江九洲药业股份有限公司

制证完毕－已发批件

2014-09-09 批准临床

CYHS1200255

甲磺酸伊马替尼片

仿制 62012-07-

13

南京先声东元制药有限公司

制证完毕－已发批件

2013-07-12 批准临床

CYHS1200838

甲磺酸伊马替尼胶

囊仿制 6

2012-11-08

江苏万高药业有限

公司

制证完毕－已发批件

2014-09-03 批准临床

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 11/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CYHS1290119

甲磺酸伊马替尼片

仿制 62012-12-

20

江苏豪森药业股份有限公司

制证完毕－已发批件

2013-07-03 批准生产

CXHS1200336

甲磺酸伊马替尼

新药 3.12012-12-

21

江苏豪森医药集团连云港宏创医药有

限公司

制证完毕－已发批件

2013-07-03 批准生产

JXHL1300002

甲磺酸伊马替尼

进口2013-01-

14

北京法马苏提克咨询有限公

司

制证完毕－已发批件

2015-12-17 不批准

CXHS1200263

甲磺酸伊马替尼

新药 3.12013-01-

28

珠海联邦制药股份有限公司

制证完毕－已发批件

2015-10-28 批准临床

CYHS1201285

甲磺酸伊马替尼胶

囊仿制 6

2013-02-04

珠海联邦制药股份有限公司中山分公

司

制证完毕－已发批件

2016-01-22 批准临床

CYHS1201598

甲磺酸伊马替尼片

仿制 62013-02-

04

杭州中美华东制药有限公司

制证完毕－已发批件

2015-12-24 批准临床

CXHS1200275

甲磺酸伊马替尼

新药 3.12013-02-

06

湖北葛店人福药业有限责任

公司

制证完毕－已发批件

2013-06-18

CXHS1200332

甲磺酸伊马替尼

新药 3.12013-02-

20

山东新时代药业有

限公司

制证完毕－已发批件

2015-12-24 批准临床

CXHS1200365

甲磺酸伊马替尼

新药 3.12013-03-

07

浙江海正药业股份有限公司

制证完毕－已发批件

2015-12-24 批准临床

CXHS1200375

甲磺酸伊马替尼

新药 3.12013-04-

07

山东方明药业集团股份有限

公司

制证完毕－已发批件

2016-01-14 批准临床

CXHS1200313

甲磺酸伊马替尼

新药 3.12013-04-

28

上海创诺制药有限

公司

制证完毕－已发批件

2015-12-30 批准临床

CYHS1201806

甲磺酸伊马替尼胶

囊仿制 6

2013-05-08

浙江海正药业股份有限公司

制证完毕－已发批件

2015-12-24 批准临床

CYHS1201537

甲磺酸伊马替尼片

仿制 62013-05-

09

上海创诺制药有限

公司

制证完毕－已发批件

2015-12-30 批准临床

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 12/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JYHB1300601

甲磺酸伊马替尼片

补充申请2013-05-

20

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2014-01-22

JYHB1300602

甲磺酸伊马替尼胶

囊补充申请

2013-05-20

北京诺华制药有限

公司

制证完毕－已发批件

2014-01-22

JYHB1300600

甲磺酸伊马替尼片

补充申请2013-05-

20

Novartis

PharmaSchweiz

AG

制证完毕－已发批件

2014-01-22

CYHS1201658

甲磺酸伊马替尼片

仿制 62013-05-

28

山东新时代药业有

限公司

制证完毕－已发批件

2015-12-30 批准临床

CXHS1300050

甲磺酸伊马替尼

新药 3.12013-06-

18

山东金城钟化生物药业有限

公司

制证完毕－已发批件

2016-01-21 批准临床

CYHS1300265

甲磺酸伊马替尼片

仿制 62013-07-

01

重庆圣华曦药业股份有限公

司

制证完毕－已发批件

2015-12-30 批准临床

CXHS1300051

甲磺酸伊马替尼

新药 3.12013-07-

01

重庆圣华曦药业股份有限公

司

制证完毕－已发批件

2015-12-30 批准临床

CYHS1300266

甲磺酸伊马替尼片

仿制 62013-07-

15

重庆圣华曦药业股份有限公

司

制证完毕－已发批件

2016-01-14 批准临床

CYHS1201831

甲磺酸伊马替尼片

仿制 62013-08-

07

山东方明药业集团股份有限

公司

制证完毕－已发批件

2016-01-14 批准临床

CYHS1390048

甲磺酸伊马替尼片

仿制 62013-08-

13

石药集团中奇制药技术（石家庄）有

限公司

制证完毕－已发批件

2014-10-31 批准生产

CXHS1300113

甲磺酸伊马替尼

新药 3.12013-08-

16

南京优科制药有限

公司

制证完毕－已发批件

2016-01-21 批准临床

CYHS1300340

甲磺酸伊马替尼片

仿制 62013-08-

20

海南锦瑞制药有限

公司

制证完毕－已发批件

2016-01-14 批准临床

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 13/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CXHS1300181

甲磺酸伊马替尼

新药 3.12013-08-

20

石药集团中奇制药技术（石家庄）有

限公司

制证完毕－已发批件

2014-11-06 批准生产

CXHS1300175

甲磺酸伊马替尼

新药 3.12013-09-

06

北大国际医院集团西南合成制药股份有限公司

制证完毕－已发批件

2016-01-14 批准临床

CXHS1300064

甲磺酸伊马替尼

新药 3.12013-09-

09

海南锦瑞制药有限

公司

制证完毕－已发批件

2016-01-14 批准临床

CXHS1300179

甲磺酸伊马替尼

新药 3.12013-09-

11

福建南方制药股份有限公司

制证完毕－已发批件

2015-12-30 批准临床

CYHS1301018

甲磺酸伊马替尼片

仿制 62013-09-

17

北大国际医院集团西南合成制药股份有限公司

制证完毕－已发批件

2016-01-14 批准临床

CYHS1300263

甲磺酸伊马替尼胶

囊仿制 6

2013-09-22

山东齐都药业有限

公司

制证完毕－已发批件

2016-01-14 批准临床

CYHS1300651

甲磺酸伊马替尼片

仿制 62013-09-

27

南京优科制药有限

公司

制证完毕－已发批件

2016-01-13 批准临床

CXHS1300254

甲磺酸伊马替尼

新药 3.12013-09-

29

齐鲁天和惠世制药有限公司

制证完毕－已发批件

2016-04-07

JXHS1300076

甲磺酸伊马替尼

进口2013-10-

11

天津青松华药医药有限公司

在审评审批中 2013-10-09

JYHB1301233

甲磺酸伊马替尼片

补充申请2013-10-

12

北京诺华制药有限

公司

制证完毕－已发批件

2014-08-27

CYHS1390066

甲磺酸伊马替尼片

仿制 62013-10-

12

齐鲁制药(海南)有限公司

制证完毕－已发批件

2016-03-10 企业撤回

CYHS1390065

甲磺酸伊马替尼片

仿制 62013-10-

12

齐鲁制药(海南)有限公司

制证完毕－已发批件

2016-03-10 企业撤回

CXHS1300198

甲磺酸伊马替尼

新药 3.12013-12-

17

湖北葛店人福药业有限责任

公司

制证完毕－已发批件

2016-01-22 批准临床

CYHS1390086

甲磺酸伊马替尼胶

囊仿制 6

2013-12-18

重庆市庆余堂制药有限公司

制证完毕－已发批件

2016-02-04 企业撤回

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 14/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CYHS1390085

甲磺酸伊马替尼片

仿制 62013-12-

18

重庆市庆余堂制药有限公司

制证完毕－已发批件

2016-02-04 企业撤回

CXHS1300316

甲磺酸伊马替尼

新药 3.12013-12-

20

福安药业（集团）股份有限

公司

制证完毕－已发批件

2016-01-29

CYHS1300536

甲磺酸伊马替尼片

仿制 62013-12-

27

北京双鹭药业股份有限公司

制证完毕－已发批件

2016-01-21 批准临床

CYHS1300533

甲磺酸伊马替尼片

仿制 62013-12-

27

北京双鹭药业股份有限公司

制证完毕－已发批件

2016-01-21 批准临床

CXHS1300346

甲磺酸伊马替尼

新药 3.12014-01-

03

南京先声东元制药有限公司

制证完毕－已发批件

2016-08-23

CYHS1390091

甲磺酸伊马替尼片

仿制 62014-01-

03

南京先声东元制药有限公司

制证完毕－已发批件

2016-03-10 企业撤回

CYHS1301587

甲磺酸伊马替尼片

仿制 62014-02-

19

深圳万乐药业有限

公司

制证完毕－已发批件

2015-12-24 批准临床

CYHS1301025

甲磺酸伊马替尼片

仿制 62014-02-

20

福建南方制药股份有限公司

制证完毕－已发批件

2016-01-22 批准临床

CYHS1301553

甲磺酸伊马替尼胶

囊仿制 6

2014-02-24

亿腾药业（泰州）有限公司

制证完毕－已发批件

2016-09-28 批准临床

CYHS1301552

甲磺酸伊马替尼片

仿制 62014-02-

24

亿腾药业（泰州）有限公司

制证完毕－已发批件

2016-09-26 批准临床

CYHS1301551

甲磺酸伊马替尼

仿制 62014-02-

24

亿腾药业（泰州）有限公司

在审评审批中 2014-02-21

JYHB0500197

甲磺酸伊马替尼片

补充申请2005-04-

21

北京诺华制药有限

公司已发件 2005-09-21 批准补充

JYHB0500196

甲磺酸伊马替尼片

补充申请2005-04-

21

北京诺华制药有限

公司已发通知件 2005-09-21 批准补充

JYHB1400479

甲磺酸伊马替尼片

补充申请2014-04-

14

北京诺华制药有限

公司

制证完毕－已发批件

2014-12-04

JYHB1400478

甲磺酸伊马替尼片

补充申请2014-04-

14 

制证完毕－已发批件

2014-10-28 批准补充

CYHS1400137

甲磺酸伊马替尼

仿制 62014-06-

09

四川协力制药有限

公司在审评审批中 2014-06-06

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 15/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JXHS1400038

甲磺酸伊马替尼

进口2014-07-

02

北京万全阳光医学技术有限

公司

在审评审批中 2014-07-01

JYHZ1400413

甲磺酸伊马替尼片

进口再注册

2014-07-10

北京诺华制药有限

公司

制证完毕－已发批件

2015-06-01批准再注

册

JYHZ1400412

甲磺酸伊马替尼胶

囊

进口再注册

2014-07-10

北京诺华制药有限

公司

制证完毕－已发批件

2015-05-28批准再注

册

CYHS1302204

甲磺酸伊马替尼片

仿制 62014-08-

20

福建天泉药业股份有限公司

制证完毕－已发批件

2016-02-04 批准临床

CXHS1300415

甲磺酸伊马替尼

新药 3.12014-08-

20

福建天泉药业股份有限公司

制证完毕－已发批件

2016-02-04 批准临床

CYHS1400597

甲磺酸伊马替尼片

仿制 62014-08-

20

珠海联邦制药股份有限公司中山分公

司

制证完毕－已发批件

2016-02-18 批准临床

CYHS1400596

甲磺酸伊马替尼片

仿制 62014-08-

20

珠海联邦制药股份有限公司中山分公

司

制证完毕－已发批件

2016-02-18 批准临床

JXHL1400282

甲磺酸伊马替尼片

进口2014-09-

02韩美药品株式会社

制证完毕－已发批件

2017-06-14

CYHS1401121

甲磺酸伊马替尼片

仿制 62014-10-

22

重庆药友制药有限责任公司

制证完毕－已发批件

2016-10-11 批准临床

JXHL1400372

甲磺酸伊马替尼片

进口2014-11-

13

北京万全阳光医学技术有限

公司

在审评审批中 2014-11-05

CYHS1401167

甲磺酸伊马替尼

仿制 62014-11-

28

陕西大生制药科技有限公司

在审评审批中 2014-11-26

CYHS1401168

甲磺酸伊马替尼胶

囊仿制 6

2014-11-28

西安葛蓝新通制药有限公司

制证完毕－已发批件

2016-10-18 批准临床

JXHL1400371

甲磺酸伊马替尼片

进口2014-12-

18

北京万全阳光医学技术有限

公司

在审评审批中 2014-12-16

JXHL1400394

甲磺酸伊马替尼胶

囊进口

2014-12-23

上海礼易医药科技有限公司

制证完毕－已发批件

2016-07-25

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 16/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

CYHS1400320

甲磺酸伊马替尼

仿制 62015-01-

14

苏州立新制药有限

公司在审评审批中 2015-01-08

CYHS1400370

甲磺酸伊马替尼片

仿制 62015-01-

23

江苏正大清江制药有限公司

制证完毕－已发批件

2016-10-11 批准临床

CYHS1400369

甲磺酸伊马替尼

仿制 62015-01-

23

江苏正大清江制药有限公司

在审评审批中 2015-01-21

CYHS1401894

甲磺酸伊马替尼

仿制 62015-03-

03

重庆芸峰药业有限

公司在审评审批中 2015-02-28

CYHS1401895

甲磺酸伊马替尼片

仿制 62015-03-

03

重庆芸峰药业有限

公司

制证完毕－已发批件

2016-10-11 批准临床

CYHS1401032

甲磺酸伊马替尼

仿制 62015-03-

13

广州南沙龙沙有限

公司在审评审批中 2015-03-10

CYHS1590014

甲磺酸伊马替尼胶

囊仿制 6

2015-04-03

江苏万高药业有限

公司

制证完毕－已发批件

2017-03-01 企业撤回

CYHS1402074

甲磺酸伊马替尼片

仿制 62015-05-

08

重庆莱美药业股份有限公司

制证完毕－已发批件

2016-10-24 批准临床

CYHS1402073

甲磺酸伊马替尼

仿制 62015-05-

08

重庆莱美药业股份有限公司

在审评审批中 2015-05-05

CXHS1500011

甲磺酸伊马替尼

新药 3.12015-05-

29

浙江九洲药业股份有限公司

制证完毕－已发批件

2017-04-17

JYHB1501253

甲磺酸伊马替尼片

补充申请2015-09-

08

北京诺华制药有限

公司

制证完毕－已发批件

2016-08-01

JYHB1501248

甲磺酸伊马替尼胶

囊补充申请

2015-09-08

北京诺华制药有限

公司

制证完毕－已发批件

2016-08-01

JYHB1501252

甲磺酸伊马替尼片

补充申请2015-09-

08

北京诺华制药有限

公司

制证完毕－已发批件

2016-08-01

CYHS1300970

甲磺酸伊马替尼片

仿制 62015-10-

08

辰欣药业股份有限

公司

制证完毕－已发批件

2016-08-01 批准临床

CXHS1300168

甲磺酸伊马替尼

新药 3.12015-10-

08

辰欣药业股份有限

公司

制证完毕－已发批件

2016-08-01 批准临床

CYHB1510377

甲磺酸伊马替尼

补充申请2015-12-

24

连云港宏创药业有

限公司

制证完毕－已发批件

2017-05-26

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 17/128

受理号码 药品名称 申请类型 注册分类 承办日期 企业名称 办理状态 状态开始日期 审批结论

JXHL1600005

甲磺酸伊马替尼胶

囊进口

2016-01-31

联合生物技术私人有限公司

在审评审批中 2016-01-29

CYHS1500273

甲磺酸伊马替尼

仿制 62016-05-

03

连云港杰瑞药业有

限公司在审评审批中 2016-04-29

CYHB1602551

甲磺酸伊马替尼片

补充申请2016-08-

29

江苏豪森药业集团有限公司

制证完毕－已发批件

2017-03-29

JYHB1700606

甲磺酸伊马替尼片

补充申请2017-04-

28

北京诺华制药有限

公司

制证完毕－已发批件

2017-06-19

JYHB1700607

甲磺酸伊马替尼胶

囊补充申请

2017-04-28

北京诺华制药有限

公司

制证完毕－已发批件

2017-06-19

JYHB1700646

甲磺酸伊马替尼片

补充申请2017-05-

13

北京诺华制药有限

公司

制证完毕－已发批件

2017-09-26

CYHB1702658

甲磺酸伊马替尼片

补充申请2017-06-

02

石药集团欧意药业有限公司

制证完毕－已发批件

2017-10-20

CXHR1700014

甲磺酸伊马替尼

复审2017-06-

22

浙江九洲药业股份有限公司

在审评审批中 2017-06-21

JYHB1701338

甲磺酸伊马替尼胶

囊补充申请

2017-10-27

北京诺华制药有限

公司在审评审批中 2017-10-25

JYHB1701339

甲磺酸伊马替尼片

补充申请2017-10-

27

北京诺华制药有限

公司在审评审批中 2017-10-25

JYHB1701344

甲磺酸伊马替尼片

补充申请2017-10-

27

北京诺华制药有限

公司在审评审批中 2017-10-25

CYHB1740007

甲磺酸伊马替尼片

补充申请2017-11-

03

江苏豪森药业集团有限公司

在审评审批中 2017-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 18/128

申请类型

数量

新药 进口 进口再注册 仿制 补充申请 复审0

20

40

60

剂型

数量

原料药 片剂 胶囊0

25

50

75

100

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 19/128

药品名称 来源 更新时间 操作

格列卫GLEEVEC(甲磺酸伊马替尼imatinib mesylate)口服片   查看全文

格列卫GLEEVEC(甲磺酸伊马替尼imatinib mesylate)口服片   查看全文

甲磺酸伊马替尼胶囊 NovartisPharmaSchweizAG   查看全文

格列卫GLEEVEC(甲磺酸伊马替尼imatinib mesylate)口服片 美国FDA   下载1  

GLEEVEC NOVARTIS 2001-05-10

GLEEVEC NOVARTIS 2003-04-28

GLEEVEC NOVARTIS 2003-05-20

GLEEVEC NOVARTIS 2003-12-08

GLEEVEC NOVARTIS 2005-03-18

GLEEVEC NOVARTIS 2005-10-25

GLEEVEC NOVARTIS 2006-10-23

GLEEVEC NOVARTIS 2006-10-23

GLEEVEC NOVARTIS 2006-10-23

GLEEVEC NOVARTIS 2006-09-28

GLEEVEC NOVARTIS 2009-06-05

GLEEVEC NOVARTIS 2012-01-31

GLEEVEC NOVARTIS 2015-02-03

GLEEVEC NOVARTIS 2002-02-01

承办日期

数量

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

0

10

20

30

40

50

药品说明书(41条) 隐藏

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 20/128

药品名称 来源 更新时间 操作

GLEEVEC NOVARTIS 2003-04-09

GLEEVEC NOVARTIS 2003-05-20

GLEEVEC NOVARTIS 2002-12-20

GLEEVEC NOVARTIS 2004-06-25

GLEEVEC NOVARTIS 2006-11-06

GLEEVEC NOVARTIS 2006-06-01

GLEEVEC NOVARTIS 2006-10-23

GLEEVEC NOVARTIS 2006-10-23

GLEEVEC NOVARTIS 2007-09-19

GLEEVEC NOVARTIS 2008-09-26

GLEEVEC NOVARTIS 2008-09-26

GLEEVEC NOVARTIS 2008-09-26

GLEEVEC NOVARTIS 2009-02-12

GLEEVEC NOVARTIS 2011-04-01

GLEEVEC NOVARTIS 2011-04-01

GLEEVEC NOVARTIS 2013-01-30

GLEEVEC NOVARTIS 2013-02-26

GLEEVEC NOVARTIS 2013-10-31

GLEEVEC NOVARTIS 2014-05-28

GLEEVEC NOVARTIS 2016-08-25

GLEEVEC NOVARTIS 2016-08-25

GLEEVEC NOVARTIS 2016-09-29

GLEEVEC NOVARTIS 2017-04-25

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

LAM PilotStudyWithImatinibMesylate

Drug:ImatinibMesylate 400Mg

Capsule;Drug:Placebo - Capsule

Not yetrecruiting

Lymphangioleiomyomatosis

Phase1/Phase

2United States 2017-06-01

全球临床试验情况(477条) 隐藏

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 21/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofRuxolitinib vs BestAvailableTherapy(BAT) inPatientsWithSteroid-refractoryChronicGraft vs.HostDisease(GvHD)AfterBoneMarrowTransplantation(REACH3)

Drug:Ruxolitinib;Drug:Extracorporealphotopheresis

(ECP);Drug:Low-dose methotrexate

(MTX);Drug:Mycophenolate mofetil

(MMF);Drug:mechanistic Target of

Rapamycin (mTOR)inhibitors

(everolimus orsirolimus);Drug:Infliximab;Drug:Rituxima

b;Drug:Pentostatin;Drug:Imatinib

Not yetrecruiting

Graft-versus-host Disease

Phase 3 2017-07-01

ARetrospectivePharmacokineticsandPharmacogenomicsResearchofImatinibinGastrointestinalStromalTumorTreatment

Recruiting

GastrointestinalStromal

Tumors;GermlineMutation;Somati

cMutation;Plasma

Concentration

China 2014-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 22/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Etoposide,Prednisone,Vincristine Sulfate,Cyclophosphamide, andDoxorubicin inTreatingPatientsWithAcuteLymphoblasticLeukemiaorLymphoblasticLymphoma

Drug:Cyclophosphamide;Drug:Dasatinib;Drug:Doxorubicin;Drug:Etoposide;Drug:I

matinibMesylate;Other:Labo

ratory BiomarkerAnalysis;Drug:Prednisone;Biological:Rituximab;Drug:Vincristin

e Sulfate

Recruiting

Adult AcuteLymphoblasticLeukemia;AdultLymphoblastic

Lymphoma;Philadelphia

ChromosomePositive

Phase 2 United States 2017-02-23

ImatinibMesylateandCombinationChemotherapy inTreatingPatientsWithNewlyDiagnosedPhiladelphiaChromosomePositiveAcuteLymphoblasticLeukemia

Procedure:Allogeneic Hematopoietic

Stem CellTransplantation;Drug:Cyclophosphamid

e;Drug:Cytarabine;Drug:Daunorubicin

Hydrochloride;Drug:Dexamethasone;Dru

g:DexrazoxaneHydrochloride;Drug:Doxorubicin;Drug:Etoposide;Biological:Filgrastim;Drug:Ifosfamide;Drug:Imatinib

Mesylate;Other:Laboratory Biomarker

Analysis;Drug:Leucovorin

Calcium;Drug:Mercaptopurine;Drug:Mercaptopurine;Drug:Mesna;Drug:Methotrexate;Drug:Methylprednisolone;Drug:Pegaspargase;Drug:Prednisolone;Other:Questi

onnaireAdministration;Drug:

TherapeuticHydrocortisone;Drug:Thioguanine;Drug:

Vincristine Sulfate

Not yetrecruiting

B AcuteLymphoblasticLeukemia With

t(9;22)(q34.1;q11.2);

BCR-ABL1;BCR-ABL1 Fusion

ProteinExpression;Mini

mal ResidualDisease;Philadelphia ChromosomePositive;T AcuteLymphoblastic

Leukemia;Untreated Adult AcuteLymphoblastic

Leukemia;Untreated Childhood

AcuteLymphoblastic

Leukemia

Phase 3 United States 2017-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 23/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofCemivil®(Imatinib)inChronicMyeloidLeukemiaPatientsin Jordan

Drug:Imatinib CompletedChronic Myeloid

Leukemia,Chronic Phase

Jordan 2012-08-01

Study toAssessEfficacyandSafety ofInecalcitol inImatinib-TreatedResidualChronicMyeloidLeukaemia: INIMStudy

Drug:Inecalcitol RecruitingCML, Chronic

PhasePhase 2 France 2014-02-01

SSG XXV:The Stop-GIST Trial;Discontinuation ofImatinibinPatientsWithOligo-metastatic GIST

Other:Discontinuation of imatinib

RecruitingGastrointestinalStromal Tumor

Phase 2 Norway 2017-01-01

AProspectiveRandomized PhaseII StudyEvaluating theMonitoring ofImatinibMesylatePlasmaticThroughLevel inPatientsNewlyDiagnosed WithCP-CML

Drug:Posology dosemodification;Other:a

ctive comparator

Active, notrecruiting

Leukemia,Myelogenous,Chronic, BCR-ABL Positive

[C04.557.337.539.250]

Phase 2 France 2010-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 24/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Follow-upof thePersistence of theCompleteMolecularRemission AfterStoppingImatinibChronicMyeloidLeukemia

Behavioral:Interruption of the treatment

by Imatinib

Active, notrecruiting

Chronic MyeloidLeukemia

France 2013-04-01

Malaysia-Singapore AcuteLymphoblasticLeukemia2010Study

Drug:Prednisolone;Drug:Dexamethasone;

Drug:L-Asparaginase;Drug:Vincristine;Drug:Methotrexate;Drug:Daunorubicin;Drug:Doxorubicin;Drug:Cyclophosphamide;Drug:Cyt

arabine;Drug:6-Mercaptopurine;Drug:Thioguanine;Drug:Fludarabine;Drug:Im

atinib

RecruitingAcute

LymphoblasticLeukemia (ALL)

Phase 4Malaysia;Sing

apore2008-10-01

EfficacyandSafety ofNilotinibinPatientsWith aChronicDiseaseof theGraftAgainstthe Host

Drug:ImatinibMesylate and

Nilotinib

Active, notrecruiting

Graft VersusHost Disease

Phase 2Belgium;Fran

ce2012-12-01

Pioglityazone andImatinibfor CMLPatients

Drug:Add-ontherapy

CompletedLeukemia,Myeloid,

Chronic-PhasePhase 2 France 2009-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 25/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Optimization ofTherapyin AdultPatientsWithNewlyDiagnosed AcuteLymphoblasticLeukemiaorLymphoblasticLymphoma byIndividualised,TargetedandIntensifiedTreatment

Drug:Rituximab;Drug:Nelarabine;Drug:P

EG-Asparaginase;Proced

ure:Cranialirradiation;Drug:Imatinib;Drug:Idarubicin;Drug:Dexamethasone;Drug:Cyclophosphamide;Drug:Fludara

bine;Drug:Vincristine;Drug:Mercaptopurine;Drug:VP16;Drug:

Daunorubicin(DNR);Drug:Methotrexate;Procedure:Ste

m celltransplantation;Drug:Cytarabine;Drug:Vindesine;Drug:Adriamycin;Drug:Prednisolo

ne

Recruiting

AcuteLymphoblastic

Leukemia;Lymphoblastic

Lymphoma

Phase 3 Germany 2016-08-01

Study ofImatinibDiscontinuation inChronicMyeloidLeukemiaWithDeepMolecularResponse

Drug:Pioglitazone;Other:imatinib

discontinuationRecruiting

Leukemia,Chronic Myeloid

Phase 2 Brazil 2016-06-01

PembrolizumabandImatinibinPatientsWithLocallyAdvanced/MetastaticMelanoma With c-KITMutation/Amplification

Drug:ImatinibMesylate;Other:Labo

ratory BiomarkerAnalysis;Biological:P

embrolizumab

Recruiting

Stage IIIA SkinMelanoma;Stage

IIIB SkinMelanoma;Stage

IIIC SkinMelanoma;Stage

IV SkinMelanoma

Phase1/Phase

2United States 2016-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 26/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Ph IINintedanib orIntravenousIfosfamideAdvancedMetastatic STSFailed onImatinibandSunitinib

Drug:Nintedanib;Drug:Ifosfamide

Not yetrecruiting

Sarcoma, SoftTissue

Phase 2 2017-01-01

A StudyofIntermittent DosingScheduleofImatinibinPatientsWithTyrosineKinaseInhibitorRefractory GISTs

Drug:ImatinibMesylate

RecruitingGastrointestinalStromal Tumors

(GISTs)Phase 2

Korea,Republic of

2016-01-01

DasatiniborNilotinibFollowedbyImatinibinPatientsWithNewlyDiagnosed,ChronicPhaseChronicMyeloidLeukemia

Drug:Dasatinib;Drug:Imatinib

Mesylate;Drug:Nilotinib

Recruiting

ChronicMyelogenous

Leukemia;Chronic Myeloid

Leukemia;Leukemia

Phase 2 United States 2016-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 27/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

SafetyandEfficiencyStudy ofPioglitazone inCombination WithImatinibMesylateto TreatChronicMyelogenousLeukemia

Drug:Pioglitazone;Drug:imatinib mesylate

Not yetrecruiting

Leukemia,Myelogenous,Chronic, BCR-ABL Positive

Phase 2 2016-02-01

Imatinibas Pre-operativeAnti-ColonCancerTargetedTherapy

Drug:Imatinib RecruitingColonic

NeoplasmsPhase 2 Netherlands 2016-04-01

EfficacyandMicrofilaricidalKineticsofImatinibfor theTreatment of LoaLoa

Drug:ImatinibMesylate;Drug:Place

bo

Not yetrecruiting

Loaisis Phase 2 Cameroon 2015-12-21

Genomics-BasedTargetTherapyforChildrenWithRelapsedorRefractoryMalignancy

Procedure:CancerSCAN™;Drug:Ifosfamide;Drug:Carboplatin;Drug:Etoposide;Drug:Fludarabine;Drug:Cytarabine;Drug:Pazopanib;Drug:Sorafenib;Drug:Axitinib;Drug:Crizotinib;Drug:Dasatinib;Drug:Erlotinib;Drug:Everolimus;Drug:Imatinib;Drug:Ruxolitinib;Drug:Vandetanib;Drug:Vemurafenib;Drug:Trastuzuma

b

Recruiting

RelapsedPediatric Solid

Tumor;RefractoryPediatric Solid

Tumor;RelapsedPediatric

AML;RefractoryPediatric AML

Phase 2Korea,

Republic of2015-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 28/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Imatinib'sEffect ontheSuppression ofMalariaParasitesinPatientsWithUncomplicatedPlasmodiumFalciparum Malaria

Drug:Imatinib;Drug:Dihydroartemisinin-

piperaquineRecruiting

PlasmodiumFalciparum

Malaria

Phase1/Phase

2Vietnam 2015-11-01

A PhaseIIIRandomized Trial oftheReduction ofChemotherapy inPhiladelphiaChromosome-positiveALL ofYoungAdults

Drug:Nilotinib;Drug:Methotrexate;Drug:

Aracytine (AraC);Drug:GranulocyteColony-Stimulating

Factor (G-CSF);Drug:Depomedrol;Drug:Dexamethasone;Drug:Vincristine;Drug:Imatinib;Drug:6 Mercaptopurine

(6MP)

Recruiting

PhiladelphiaChromosomePositive Adult

AcuteLymphoblastic

Leukemia

Phase 3 France 2016-04-01

A Trial ofPaclitaxelinPatientsWithMetastatic orAdvancedGastrointestinalStromalTumors(GIST)AfterFailure toImatinibandSunitinib

Drug:Paclitaxel RecruitingGastrointestinalStromal Tumors

Phase 2Korea,

Republic of2015-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 29/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

SustainedTreatment-freeRemission in BCR-ABL+ChronicMyeloidLeukemia

Drug:Imatinib;Drug:Nilotinib

Not yetrecruiting

Chronyc MyeloidLeukemia

Phase 4 Italy 2016-12-01

EfficacyofImatinibinPatientsWithIntermediate-riskGastrointestinalStromalTumorWith aHigh-riskGenomicGradeIndex

Drug:Imatinib;Other:Surveillance

Not yetrecruiting

GastrointestinalStromal Tumor

Phase 3 2015-10-01

Etoposide,Prednisone,Vincristine Sulfate,Cyclophosphamide, andDoxorubicinHydrochlorideWithAsparaginase inTreatingPatientsWithAcuteLymphoblasticLeukemiaorLymphoblasticLymphoma

Drug:Asparaginase;Drug:Cyclophosphamide;Drug:Doxorubi

cinHydrochloride;Drug:Etoposide;Drug:Imat

inibMesylate;Other:Labo

ratory BiomarkerAnalysis;Drug:Prednisone;Biological:Rituximab;Drug:Vincristin

e Sulfate

Not yetrecruiting

B AcuteLymphoblastic

Leukemia;BLymphoblastic

Lymphoma;Recurrent Adult AcuteLymphoblastic

Leukemia;Recurrent B

LymphoblasticLymphoma;Recur

rent TLymphoblastic

Leukemia/Lymphoma;Refractory B

LymphoblasticLymphoma;Refra

ctory TLymphoblasticLymphoma;T

AcuteLymphoblastic

Leukemia;TLymphoblastic

Lymphoma

Phase 2 United States 2017-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 30/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Trial ofImatinibforPatientsWithAggressiveDesmoidTumor(AggressiveFibromatosis)

Drug:ImatinibActive, notrecruiting

Fibromatosis Phase 2Korea,

Republic of2014-04-01

Treatment of CMLPatientsWithImatinibandHydroxyurea(CML2004)

Drug:Imatinib;Drug:Hydroxyurea

Completed

Leukemia,Myelogenous,Chronic, BCR-ABL Positive

Phase1/Phase

22004-04-01

BrentuximabVedotinandImatinibinPatientsWithRelapsedorRefractory ALK+ALCL

Drug:Brentuximabvedotin;Drug:Imatini

bRecruiting

ALK+ AnaplasticLarge Cell

Lymphoma

Phase1/Phase

2Austria 2015-05-01

PatientsWithRefractory,Metastatic CancerHarboring KITMutationorAmplification toInvestigate theClinicalEfficacyandSafety ofImatinibTherapy

Drug:Imatinib RecruitingAdvanced,Refractory

CancerPhase 2

Korea,Republic of

2014-04-04

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 31/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ESHAP-ImatinibforRefractory/Relapsed Non-Hodgkin'sLymphoma

Drug:ESHAP-Imatinib

RecruitingLymphoma,

Non-Hodgkin

Phase1/Phase

2

Korea,Republic of

2015-02-01

ExtensionStudy ofIDEAL(Imatinib)forChronicMyelgenousLeukemia(CML)

Drug:IDEAL-Eobservation

(investigators choiceof imatinib, nilotinib,dasatinib, radotinib)

Withdrawn

Leukemia,Myelogenous,Chronic, BCR-ABL Positive

Korea,Republic of

2014-10-01

ThreeVersusFive YearsofAdjuvantImatinibasTreatment ofPatientsWithOperableGIST

Drug:Imatinib Recruiting Sarcoma Phase 3 Finland 2015-05-01

Activityand RiskProfile ofPonatinibinChronicPhasePatientsWithChronicMyeloidLeukemiaResistanttoImatinib

Drug:Ponatinib RecruitingChronic MyeloidLeukemia;Chroni

c Phase;AdultsPhase 2 Italy 2016-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 32/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ARandomised Trial ofImatinibAlternating WithRegorafenibCompared toImatinibAlone forthe FirstLineTreatment ofAdvancedGastrointestinalStromalTumour(GIST)

Drug:Regorafenib;Drug:imatinib

RecruitingGastrointestinalStromal Tumour

Phase 2

Australia;Finland;France;Netherlands;Norway;Singapore;Slovakia;Spain;Sweden;U

nitedKingdom

2015-02-01

Treatment ofCervicalSpinalCordInjuryWithImatinib -a SafetyandFeasibilityStudy

Drug:ImatinibUnknown

statusCervical Spinal

Cord InjuryPhase 2 2015-03-01

A Studyof BBI608in AdultPatientsWithAdvanced,RefractoryHematologicMalignancies

Drug:BBI608;Drug:Dexamethasone;Drug:Bortezomib;Drug:Imatinib;Drug:Ibrutinib

Active, notrecruiting

HematologicMalignancy

Phase 1 United States 2015-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 33/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Optimization ofTKIsTreatment andQuality ofLife inPh+ CMLPatients≥60 Yearsin DeepMolecularResponse

Drug:imatinib;Drug:nilotinib;Drug:dasati

nibRecruiting

Leukemia,Chronic Myeloid

Phase 3 Italy 2015-06-01

EfficacyandSafety ofImatinibMesylateas First-lineTreatment for thePatientsWithChronicPhase ofChronicMyeloidLeukemia

Drug:ImatinibNot yet

recruitingChronic Myeloid

LeukemiaPhase 4 2015-02-01

Combination ofGemcitabine andImatinibMesylateinPemetrexed-pretreated PatientsWithPleuralMesothelioma

Drug:Gemcitabine;Drug:Imatinib

mesylate

Active, notrecruiting

Mesothelioma,Malignant

Phase 2 Italy 2014-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 34/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofImatinibandNilotinibinPatientsWithChronicMyelogenousLeukemiainChronicPhase

Drug:Imatinib;Drug:Nilotinib

Completed Leukemia Phase 3 China 2014-07-17

DovitinibinCombination WithImatinibinPatientsWithGastrointestinalStromalTumors

Drug:dovitinib plusimatinib

WithdrawnGastrointestinalStromal Tumors

Phase 1 2015-03-01

EfficiencyofImatinibTreatmentMaintenance orInterruption After 3Years ofAdjuvantTreatment inPatientsWithGastrointestinalStromalTumours(GIST)

Drug:Imatinibmaintenance

Recruiting

GastrointestinalStromal

Tumors;ResectedGastrointestinal

StromalTumors;Non-

metastatic;HighRisk of

Recurrence;KITGene Mutation

Phase 3 France 2014-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 35/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

BGJ398 inCombination WithImatinibMesylateinPatientsWithUntreatedAdvancedGastrointestinalStromalTumor(GIST)

Drug:BGJ398;Drug:Imatinib Mesylate

Active, notrecruiting

AdvancedGastrointestinalStromal Tumor

(GIST)

Phase1/Phase

2United States 2014-10-02

A StudytoEvaluateEfficacyandSafety ofGlinib inNewlyDiagnosed CMLPatients

Drug:600mg/day ofImatinib;Drug:400m

g/day of Imatinib

Active, notrecruiting

Chronic MyeloidLeukemia

Phase 4Korea,

Republic of2014-09-01

The Studyof theEfficacyand theSafety ofFlumatinib vsImatinibas FirstLineTreatment inPatientsWith CML

Drug:Flumatinib600mg

qd;Drug:Imatinib400mg qd

Unknownstatus

CML, CML-CP,MMR,TKI

Phase 3 China 2014-06-01

Influenceof anAcidicBeverageon theImatinibExposureAfterMajorGastrectomy

DietarySupplement:cola

Terminated

GastrointestinalStromal

Tumor;MajorGastrectomy

Phase 1 Netherlands 2014-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 36/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofImatinibMesylateinNeurofibromatosisType IPatientsAged 2 to21 WithPlexiformNeurofibromas

Drug:ImatinibMesylate

RecruitingPlexiform

NeurofibromasPhase 2 Canada 2014-06-01

An Open-label,RandomisedMulticenter Phase3b StudytoDetermine theConfirmed Rate ofMolecularResponse≥ 4 Log(MR4) atTwoYears

Drug:Imatinib;Drug:Nilotinib

RecruitingChronic Myeloid

LeukemiaPhase 3 Germany 2014-03-01

PopulationPharmacokineticsofImatinibin CMLPatientsin Iran

Drug:Imatinib TerminatedChronic

MyelogenousLeukemia

Iran, IslamicRepublic of

2012-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 37/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

AMulticenter Phase3, Open-LabelStudy ofBosutinibVersusImatinibin AdultPatientsWithNewlyDiagnosed ChronicPhaseChronicMyelogenousLeukemia

Drug:Bosutinib;Drug:Imatinib

Active, notrecruiting

Leukemia,Myelogenous,

Chronic,Breakpoint

Cluster Region-Abelson Proto-

oncogene (BCR-ABL) Positive

Phase 3

UnitedStates;Canada;Australia;Belgium;Czech

Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Kore

a, Republicof;Mexico;Netherlands;Norway;Poland;Singapore;Slov

akia;SouthAfrica;Spain;Sweden;Taiwan;Thailand;Ukraine;United

Kingdom

2014-06-01

ExploretheSynergyofCombination TKITherapy

Drug:Dasatinib;Drug:Dasatinib+Imatinib

WithdrawnHealthy

VolunteersPhase 1 2014-09-01

Imatiniband BL-8040(NovelAntiCXCR4Antagonist) forImprovingMolecularResponseinChronicMyelogenousLeukemia

Drug:BL-8040 WithdrawnChronic Myeloid

Leukemia

Phase1/Phase

2Israel 2014-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 38/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Trial toEvaluatetheImprovement ofChronicLow-grade AEsinPatientsWith Ph+CML WithOptimalResponsetoImatinibWhenSwitchedtoNilotinib

Drug:Nilotinib Recruiting

PhiladelphiaPositive (Ph+)

Chronic MyeloidLeukemia

Phase 3Russian

Federation2015-12-01

ComparativeBioequivalenceStudy inAdultPatientsSufferingFromChronicMyeloidLeukemia&GastrointestinalStromalTumorUnderFedConditions

Drug:ImatinibMesylate Tablets,

400mg;Drug:ImatinibMesylate Tablets,

400 mg

Completed

Chronic MyeloidLeukemia;Gastrointestinal Stromal

Tumor

Phase2/Phase

3India 2014-02-01

EfficacyandSafetyAssessment ofNIlotinibin CMLPatientsWithSuboptimalResponseonImatinibTherapy

Drug:Nilotinib 300mg.

TerminatedMyeloid

Leukemia,Chronic

Phase 4 Saudi Arabia 2013-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 39/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Phase IStudy ofOralABL001 inPatientsWith CMLor Ph+ALL

Drug:ABL001;Drug:ABL001 +

Nilotinib;Drug:ABL001;Drug:ABL001+imatinib;Drug:ABL001+

dasatinib

Recruiting

ChronicMyelogenous

Leukemia;Philadelphia

Chromosome-positive AcuteLymphoblastic

Leukemia

Phase 1

UnitedStates;Australia;France;Germany;Italy;Ja

pan;Korea,Republic

of;Netherlands;Singapore;S

pain

2014-04-24

Patternsof ABLMutationin AsianWithImatinibResistantChronicMyeloidLeukemiaand PhPositiveAcuteLymphocytcLeuekmiaPatients(AMICA)

Unknownstatus

Chronic MyeloidLeukemia or Ph

Positive ALL

Korea,Republic of

2010-07-01

A PilotStudy ofGenomicSequencingGuidedIndividualizedTherapyinGastrointestinalCancers,GITICStudy

Drug:Erlotinib orGefitinib;Drug:Everolimus;Drug:Imatinib;Drug:Sorafenib or

Sunitinib;Drug:Vandetanib

RecruitingGastrointestinal

CancersChina 2013-12-01

PegylatedInterferonAlfa-2bandNilotinibforAugmentation ofCompleteMolecularResponseinChronicMyeloidLeukaemia

Drug:Nilotinib,Pegylated interferon

alpha-2b, ImatinibRecruiting

Chronic MyeloidLeukaemia

Phase 2 Australia 2014-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 40/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

MEK162inCombination WithImatinibMesylateinPatientsWithUntreatedAdvancedGastrointestinalStromalTumor(GIST)

Drug:MEK162;Drug:Imatinib Mesylate

(Gleevec®; STI571;NSC

#716051);Other:Blood

draws;Procedure:biopsy

RecruitingGastrointestinalStromal Tumor

(GIST)

Phase1/Phase

2United States 2013-11-01

Phase IIITrialEvaluating theEffectiveness of aDoseAdjustment ofImatinibMesylateon theMolecularResponse

Drug:ImatinibMesylate

RecruitingLeukemia,Myeloid,

Chronic-PhasePhase 3 France 2009-07-01

Low-doseNilotinibandImatinibCombination inChronicMyeloidLeukemiaPatients,WithFailure,SuboptimalResponseorTreatmentIntolerance

Drug:Imatinib andNilotinib

Completed

Leukemia,Myeloid,

Chronic, BCR-ABL Positive

Phase 3 Mexico 2012-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 41/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

De-EscalationandStoppingTreatment ofImatinib,Nilotinibor sprYcelinChronicMyeloidLeukaemia

Drug:Imatinib;Drug:nilotinib;Drug:dasati

nib

Active, notrecruiting

Chronic MyeloidLeukaemia

Phase 2United

Kingdom2013-12-01

BioequivalenceStudy ofMesylateImatinibCapsuleinChronicMyeloidLeukemiaBody

Drug:mesylateimatinib

capsule;Drug:GlivecCompleted

Chronic MyeloidLeukemia

Phase 1 China 2012-09-01

A Phase IIStudy ofImatinibVersusInterferonasAdjuvantTherapyin KIT-mutatedMelanoma

Drug:imatinib;Drug:Interferon

Unknownstatus

Melanoma Phase 2 China 2012-08-01

ImatinibTreatment inRecentOnsetType 1DiabetesMellitus

Drug:ImatinibMesylate;Drug:Place

bo (For imatinibmesylate)

Active, notrecruiting

DiabetesMellitus, Type

I;DiabetesMellitus, Insulin-

Dependent,1;Type 1Diabetes

Mellitus;Insulin-Dependent

Diabetes Mellitus1;IDDM

Phase 2United

States;Australia

2014-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 42/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ARandomized PhaseII TrialComparing TherapyBased onTumorMolecularProfilingVersusConventionalTherapyinPatientsWithRefractory Cancer

Drug:Targetedtherapy based on

molecular profiling :Imatinib;Procedure:T

umorbiopsy;Drug:Standar

dChemotherapy;Drug:

Targeted therapybased on molecular

profiling :Everolimus;Drug:Targeted therapy based

on molecularprofiling :

Vemurafenib;Drug:Targeted therapy

based on molecularprofiling :

Sorafenib;Drug:Targeted therapy based

on molecularprofiling :

Erlotinib;Drug:Targeted therapy based onmolecular profiling :

Lapatinib +Trastuzumab;Drug:T

argeted therapybased on molecular

profiling :Dasatinib;Drug:Targeted therapy based

on molecularprofiling : Tamoxifen

(or letrozole ifcontra-

indication);Drug:Targeted therapy based

on molecularprofiling :

Abiraterone

Active, notrecruiting

Reccurent/Metastatic Solid Tumor

DiseasePhase 2 France 2012-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 43/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Phase IIIStudy ofCompoundFormulaRealgar-IndigoNaturalisPlusImatinibVersusPlaceboPlusImatinibin AdultCML-CPPatientsWith Ph+

Drug:Compoundrealgar natural

indigoTablet;Drug:placebo

Enrolling byinvitation

ChronicMyelogenous

LeukemiaPhase 3 China 2012-11-01

A ClinicalTrial toComparethePharmacokineticsofImatinibMesylateTablet400mg (1Tablet)andGlivecFilm-coatedTablet100mg (4Tablets)(Phase I)

Drug:Imatinibmesylate tablet 400

mg, 1Tablet;Drug:Glivecfilm-coated tablet100 mg, 4 Tablets

Completed

Chronic MyeloidLeukemia;Gastrointestinal Stromal

Tumor

Phase 1Korea,

Republic of2012-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 44/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PonatinibasSecondLineTherapyforPatientsWithChronicMyeloidLeukemiainChronicPhaseResistantorIntoleranttoImatinib,DasatiniborNilotinib

Drug:PonatinibActive, notrecruiting

Leukemia Phase 2 United States 2013-01-01

Study toAllowAccess toImatinibforPatientsWho AreonImatinibTreatment in aNovartis-sponsored Studyand AreBenefiting FromtheTreatment asJudgedby theInvestigator

Drug:STI571Active, notrecruiting

GIST and CML Phase 4

UnitedStates;China;Finland;France;

HongKong;Romania;Singapore;Switzerland;Thailand;Turkey;

UnitedKingdom

2013-03-01

Ipilimumab andImatinibMesylateinAdvancedCancer

Drug:Ipilimumab;Drug:Imatinib

MesylateRecruiting

AdvancedCancers

Phase 1 United States 2013-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 45/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Dose-findingStudy ofaCombination ofImatinibandBYL719 intheTreatment of 3rdLine GISTPatients

Drug:ST571 +BYL719

Active, notrecruiting

3rd Line GIST Phase 1

UnitedStates;Belgium;France;Germany;Italy;Netherlands;Spa

in;UnitedKingdom

2013-02-01

Additionof P1101toImatinibTreatment inPatientsWithChronicPhaseChronicMyeloidLeukaemia NotAchievingaCompleteMolecularResponse

Drug:P1101 RecruitingChronic Phase

Chronic MyeloidLeukemia

Phase 1 Austria 2013-08-01

toEvaluatethePharmacokinetics(Cmax, Auc)of CJImatinibMesylateTablet200mg x1Compared WithGleevecFilm-coatedTablet100mg x2 inHealthyMaleVolunteers

Drug:CJ Imatinibmesylate

tablet;Drug:Gleevecfilm-coated tablet 2

x 100mg

Completed Healthy Phase 1Korea,

Republic of2012-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 46/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

EfficacyandSafety ofPD-0332991inPatientsWithAdvancedGastrointestinalStromalTumorsRefractory toImatinibandSunitinib

Drug:PD-0332991will be

administrated orally,formulated as

gelatin capsules of100 mg and 25 mg

respectively.

RecruitingAdvanced

GastrointestinalStromal Tumors

Phase 2 France 2013-08-01

ImatinibMesylateandMycophenolateMofetilforSteroid-RefractorySclerotic/FibroticcGVHD inChildren

Drug:Imatinibmesylate,

Mycophenolatemofetil

RecruitingChronic Graft-

versus-hostDisease

Phase 2Korea,

Republic of2013-08-01

SurgeryforLocallyUnresectableAdvancedGISTsWithoutMetastasis AfterImatinibTherapy

RecruitingGastrointestinalStromal Tumor

Phase 2 Taiwan 2012-04-01

TyrosIneKinaseInhibitorsinChronicMyeloidLeukemia:EfficacyandTolerability. TheTIKletStudy

Drug:Imatinib/Nilotinib

Unknownstatus

Chronic MyeloidLeukemia

Italy 2013-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 47/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Phase 3Study toEvaluateEfficacyandSafety ofMasitinibinComparison toSunitinibinPatientsWithGastrointestinalStromalTumourAfterProgression WithImatinib

Drug:Masitinib;Drug:Sunitinib

Unknownstatus

GastrointestinalStromal Tumors

Phase 3 France 2012-04-01

Phase IIStudy ofGleevec/ImatinibMesylate(STI-571,NCS716051)inNeurofibromatosis(NF1)PatientsWithPlexiformNeurofibromas

Drug:Gleevec CompletedNeurofibromatos

isPhase 2 United States 2006-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 48/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Phase IV,Open-label,Multicenter StudyofDasatinibinChronic-PhaseChronicMyeloidLeukemia(CP-CML)PatientsWithChronic,Low-gradeNon-HematologicToxicitytoImatinib

Drug:Dasatinib CompletedChronic Phase

Chronic MyeloidLeukemia

Phase 4

UnitedStates;France;Germany;Italy

;Korea,Republic of

2012-12-01

Megavec400 mg(ImatinibMesylate)inHealthyAdultMaleVolunteers

Drug:Megavec;Drug:Glivec

Completed Healthy Phase 1 2012-01-01

Ponatinibin NewlyDiagnosed ChronicMyeloidLeukemia(CML)(EPIC)

Drug:ponatinib;Drug:imatinib (Gleevec/

Glivec)Terminated

Chronic MyeloidLeukemia

Phase 3

UnitedStates;Canada;Australia;Austria;Belgium;

CzechRepublic;Finland;France;Ger

many;HongKong;Italy;Korea, Republicof;Netherland

s;NewZealand;Poland;Portugal;P

uertoRico;Singapore;Slovakia;Spain;Sweden;Switzerland;Tai

wan;UnitedKingdom

2012-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 49/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibResponseinPatientsWithChronicMyeloidLeukemia(CML) inFunctionof AblPolymorphisms

WithdrawnLeukemia,Myeloid,

Chronic-PhaseFrance 2014-12-01

Study ofDasatinibvsImatinibinPatientsWithChronicMyeloidLeukemia(CML)Who DidNot HaveFavorableResponsetoImatinib

Drug:Imatinib;Drug:Dasatinib

Active, notrecruiting

Chronic PhaseChronic Myeloid

LeukemiaPhase 2

UnitedStates;Canada;Argentina;Austria;Belgium;Brazil;Chin

a;CzechRepublic;France;Hungary;It

aly;Korea,Republic

of;Poland;Spain;Thailand

2012-10-01

Validation ofDigital-PCRAnalysisThroughProgrammedImatinibInterruption in PCRNegativeCMLPatients

Drug:Imatinibmesylate

Active, notrecruiting

Chronic MyeloidLeukemia

Phase 4Canada;Germany;Israel;Ital

y;Spain2011-11-01

ImatinibandCarvedilolfor HighBloodPressurein theLungs inAdultsWithSickle CellDisease

Drug:Carvedilol;Drug:Imatinib

WithdrawnPulmonary

HypertensionPhase 1 2012-03-02

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 50/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

DiscontinuationStudy ofImatinibin AdultCP CMLPatientsWhoHave aCompleteMolecularResponsetoImatinib

Behavioral:Imatinibtreatment

discontinuing

Unknownstatus

Chronic MyeloidLeukemia;Imatini

b;CompleteMolecularResponse

Korea,Republic of

2010-06-01

ProspectiveInvestigation ofDynamicsof ABLMutations inImatinibFailedCMLPatientsTreatedWithNilotinib

Drug:NilotinibUnknown

statusChronic Myeloid

LeukemiaPhase 2

Korea,Republic of

2011-07-01

Proof ofConceptTrial ofGleevec(Imatinib)in ActiveDiffuseScleroderma

Drug:Imatinibmesylate;Other:Place

boTerminated Scleroderma Phase 2 Canada 2008-04-01

ImatinibDoseEscalationto 800mg/Dayin KoreanPatientsWithMetastatic orUnresectable GISTHarboring KITExon 9Mutation

Drug:imatinib RecruitingGastrointestinalStromal Tumors

Phase 2Korea,

Republic of2012-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 51/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Pazopanib inAdvancedGastrointestinalStromalTumorsRefractory toImatinibandSunitinib

Drug:PazopanibActive, notrecruiting

GastrointestinalStromal Tumors

Phase 2

Denmark;Finland;Germany;Norway;Swed

en

2012-02-01

RadotinibVersusImatinibin NewlyDiagnosedPhiladelphiaChromosome andChronicMyeloidLeukemiaChronicPhasePatients

Drug:Imatinib;Drug:Radotinib

Completed

Leukemia;Leukemia,

Myeloid;Leukemia, Myelogenous,

Chronic, BCR-ABL

Positive;Philadelphia

Chromosome;Bone Marrow

Diseases;Hematologic Diseases

Phase 3

Indonesia;Korea, Republic

of;Philippines;Thailand

2011-08-01

A Phase 2Study toEvaluateEfficacyandSafety ofMasitinibinComparison toSunitinibinPatientsWithGastro-IntestinalStromalTumourResistanttoImatinib

Drug:masitinib;Drug:sunitinib

Unknownstatus

Gastro IntestinalStromal Tumor

Phase 2 France 2008-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 52/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Phase IIStudy ofFlumatinib VersusImatinibto TreatPhiladelphiaChromosomePositiveChronicMyelogenousLeukemia

Drug:flumatinib;Drug:imatinib

Unknownstatus

MyelogenousLeukemia,

ChronicPhase 2 China 2011-08-01

Chemotherapy andImatinibin YoungAdultsWithAcuteLymphoblasticLeukemiaPh (BCR-ABL)POSITIVE

Drug:Imatinib Recruiting

AcuteLymphoblasticLeukemia Ph

Positive

Phase 4 Spain 2008-01-01

PilotStudy toAssessTelemonitoring ofGleevec(ImatinibMesylate)orTasigna(Niltinib)Therapy

Behavioral:no accessto

eMedonline;Behavioral:eMedonline

access

Active, notrecruiting

Chronic PhaseCML

United States 2009-04-01

Phase llStudy ofImatinibMesylatefor theNeoadjuvantTreatment ofPatientsWithGastrointestinalStromalTumors(GIST)

Drug:imatinibmesylate

CompletedGastrointestinalStromal Tumors

Phase 2 Brazil 2008-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 53/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

EfficacyandSafety ofDovitinibinPatientsWithGastrointestinalStromalTumorsRefractory and/orIntoleranttoImatinib

Drug:Dovitinib(TKI258)

CompletedGastrointestinalStromal Tumors

Phase 2Finland;France;Germany;Ita

ly;Spain2012-01-01

ObservationalStudy inAdultsWithImatinib-resistant/IntolerantChronicMyeloidLeukemiaTreatedWithNilotinib

Drug:Imatinib RecruitingChronic Myeloid

LeukaemiaItaly 2012-02-01

A Dose-findingStudy ofaCombination ofImatinibandBKM120in theTreatment of 3rdLine GISTPatients

Drug:STI571;Drug:BKM120

Completed 3rd Line GIST Phase 1

UnitedStates;Canada;Belgium;France;Japan;Netherlands;Spa

in;UnitedKingdom

2012-04-19

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 54/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Comparison ofImatinibVersusDasatinibinPatientsWithNewly-diagnosed ChronicPhaseChronicMyeloidLeukaemia

Drug:Imatinib;Drug:Dasatinib

Recruiting

MyeloidLeukemia,

Chronic, ChronicPhase

Phase 3United

Kingdom2008-08-01

DovitinibforImatinib/Sumitinib-failedGastrointestinalStromalTumors(GIST)

Drug:dovitinib CompletedGastrointestinalStromal Tumors

Phase 2Korea,

Republic of2011-09-01

PharmacogenomicsValidation forImatinibinChronicMyeloidLeukemia

Completed

Leukemia,Myelogenous,Chronic, BCR-ABL Positive

Canada;Korea, Republic of

2011-09-01

DasatinibandCyclosporine inTreatingPatientsWithChronicMyelogenousLeukemiaRefractory orIntoleranttoImatinibMesylate

Drug:dasatinib;Other:diagnosticlaboratorybiomarker

analysis;Other:pharmacological

study;Drug:cyclosporine

Terminated

AcceleratedPhase ChronicMyelogenous

Leukemia;Chronic MyelogenousLeukemia, BCR-

ABL1Positive;ChronicPhase ChronicMyelogenous

Leukemia;Relapsing Chronic

MyelogenousLeukemia

Phase 1 United States 2011-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 55/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Drug-drugInteraction StudyWithMetformin andImatinib

Drug:Metformin;Drug:Imatinib

Completed Healthy Phase 1 United States 2011-10-01

EfficacyofNilotinibVersusImatinibin Ph+CML inEarly CPWhoHave aSuboptimalMolecularResponsetoImatinib

Drug:Nilotinib,Imatinib

Unknownstatus

Chronic MyeloidLeukemia

Phase 3Korea,

Republic of2009-01-01

ExtensiontoCQTI571A2102 toEvaluateLong-termSafety,Tolerability andEfficacyofImatinibin SeverePulmonary ArterialHypertension(PAH)

Drug:Imatinib TerminatedPulmonary

ArterialHypertension

Phase 3

UnitedStates;Australia;Belgium;Germany;Italy;Lithuania;United

Kingdom

2011-06-01

PharmacokineticEffects ofQTI571onSildenafilandBosentaninPulmonary ArterialHypertensionPatients

Drug:Imatinib TerminatedPulmonary

ArterialHypertension

Phase 3

UnitedStates;Australia;Belgium;Germany;Italy;Lithuania;United

Kingdom

2011-04-20

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 56/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Pazopanib inImatinibRefractory orIntolerantGastrointestinalStromalTumors(GIST)

Drug:Pazopanib TerminatedGastrointestinalStromal Tumor

(GIST)Phase 2 United States 2011-07-01

EntinostatAndImatinibMesylateInTreatingPatientsWithRelapsedorRefractoryPhiladelphiaChromosome-PositiveAcuteLymphoblasticLeukemia

Drug:entinostat;Drug:imatinib

mesylate;Other:laboratory biomarker

analysis;Other:pharmacological

study;Genetic:western

blotting;Other:immunohistochemistry

stainingmethod;Other:flow

cytometry;Genetic:polymerase chain

reaction;Other:highperformance liquidchromatography;Ot

her:massspectrometry

Terminated

PhiladelphiaChromosomePositive Adult

Precursor AcuteLymphoblastic

Leukemia;Recurrent Adult AcuteLymphoblastic

Leukemia

Phase1/Phase

2United States 2010-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 57/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofOralAMN107(Nilotinib)in AdultPatientsWithImatinib -Resistantor -IntolerantChronicMyeloidLeukemiain BlastCrisis,Accelerated PhaseorChronicPhasePreviously EnrolledtoCAMN107A2109Trial

Drug:nilotinib CompletedChronic

MyelogenousLeukemia

Phase 4 Poland 2008-12-01

Multicenter TrialEstimating thePersistence ofMolecularRemission inChronicMyeloidLeukaemia in LongTermAfterStoppingImatinib

Drug:Imatinib stopActive, notrecruiting

Chronic MyeloidLeukaemia

France 2011-04-01

Hyper-CVADWithLiposomalVincristine in AcuteLymphoblasticLeukemia

Drug:Rituximab;Drug:Imatinib;Drug:Cyclophosphamide;Drug:Doxorubicin;Drug:Mesna;Drug:VSLI;Drug

:Solu-Medrol;Drug:Methot

rexate;Drug:Ara-C;Drug:G-

CSF;Drug:Pegfilgrastim;Drug:Dexamethas

one

Recruiting Leukemia Phase 2 United States 2013-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 58/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Bortezomib,Vorinostat andDexamethasoneforRelapsed/Refractory AcuteLymphoblasticLeukemia(ALL)

Drug:Bortezomib;Drug:Vorinostat;Drug:Dexamethasone;Drug:Methotrexate;Drug:Imatinib mesylate

TerminatedAcute

LymphoblasticLeukemia

Phase 2 United States 2011-06-01

ImatinibandRituximabinTreatingCutaneousSclerosisinPatientsWithChronicGraft-Versus-HostDisease

Drug:imatinibmesylate;Biological:r

ituximabCompleted

Graft VersusHost

Disease;SystemicScleroderma

Phase 2 United States 2011-03-01

Imatinibin KIT-negativeSystemicMastocytosis

Drug:ImatinibMesylate

CompletedSystemic

MastocytosisPhase 4 Spain 2011-01-01

A StudytoInvestigate theSafetyandEfficacyofAT13387,Alone orinCombination WithImatinib,inPatientsWith GIST

Drug:AT13387 andImatinib

CompletedGastrointestinalStromal Tumor

(GIST)Phase 2 United States 2011-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 59/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A GlobalImatinibandNilotinibPregnancyExposureRegistry

Drug:Tasigna;Drug:Gleevec

Completed

All Indicationsfor

Glivec/Gleevecand Tasigna

United States 2011-01-01

EfficacyofNilotinibin AdultPatientsWithGastrointestinalStromalTumorsResistanttoImatinibandSunitinib.

Drug:Nilotinib CompletedGastrointestinalStromal Tumors

Phase 3 Germany;Italy 2008-11-01

Everolimus inCombination WithImatinibMesylateinTreatingPatientsWithLocallyAdvanced, LocallyRecurrent, orMetastatic SoftTissueSarcoma

Other:diagnosticlaboratorybiomarker

analysis;Drug:everolimus;Drug:imatinib

mesylate

Completed

Adult SynovialSarcoma;Recurre

nt Adult SoftTissue

Sarcoma;Stage IIIAdult Soft Tissue

Sarcoma;StageIV Adult Soft

Tissue Sarcoma

Phase1/Phase

2United States 2011-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 60/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study toEvaluateNilotinibin AdultPatientsWithImatinib-resistantorImatinib-intolerantChronicMyelogenousLeukemia(CML), orRelapse/RefractoryPh+AcuteLymphoblasticLeukemia(ALL)(Extension Study)

Drug:Nilotinib Completed

ChronicMyelogenous

Leukemia;AcuteLymphoblastic

Leukemia

Phase1/Phase

2Japan 2005-08-01

Everolimus inCombination WithImatinibinPatientsWithGlivecRefractory/ResistantGastrointestinalStromalTumors

Drug:Everolimus;Drug:Imatinib

CompletedGastrointestinalStromal Tumors

Phase1/Phase

2

UnitedStates;Belgium;France;Ger

many

2002-11-01

SafetyandEfficacyofNilotinibvs.Imatinibin theTreatment ofNewlyDiagnosed ChinesePh+CML-CPPatients

Drug:Nilotinib;Drug:Imatinib

CompletedChronic Myeloid

LeukemiaPhase 3 China 2011-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 61/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Glivec®Plus m-FOLFOXAvastin®inAdvancedColorectal Cancer

Drug:Imatinib,Fluorouracil,Oxaliplatin,

Leucovorin andBevacizumab

TerminatedAdvancedColorectal

CancerPhase 1 Australia 2007-10-01

PerioperativeImatinibMesylateinTreatingPatientsWithLocallyAdvancedGastrointestinalStromalTumor

Drug:imatinibmesylate;Procedure:

conventionalsurgery

CompletedGastrointestinalStromal Tumor

Phase 2 China 2010-05-01

ARetrospective Studyof C-kitMutationStatus inAsianPatientsWithAdvancedGastro-intestinalStromalTumors(GIST)TreatedWithImatinib.

Procedure:Tumorbiopsies

Unknownstatus

Asian PatientsWith Advanced

Gastro-intestinalStromal Tumors(GIST) TreatedWith Imatinib

Singapore 2011-09-01

A StudyComparingImatinibandImatinib/PegylatedInterferoninChronicMyeloidLeukemia

Drug:imatinib andpegylated interferon

CompletedHealth Care

Quality;HealthCare Evaluation

Phase 2 Sweden 2004-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 62/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateWith orWithoutHydroxychloroquine inTreatingPatientsWithChronicMyeloidLeukemia

Drug:hydroxychloroquine;Drug:imatinibmesylate;Genetic:cyt

ogeneticanalysis;Genetic:poly

merase chainreaction;Other:labor

atory biomarkeranalysis;Other:pharmacological study

Unknownstatus

Leukemia Phase 2United

Kingdom2010-03-01

Study forSafetyandEfficacyEvaluation ofImatinibMesylateinChildrenWithAcuteLymphoblasticLeukemia(ALL)PhiladelphiaChromosome-positive(Ph+)

Drug:ImatinibMesylate

Suspended

AcuteLymphoblasticLeukemia (ALL)

PhiladelphiaChromosome-positive (Ph+)

Phase 2

Phase IIStudy forSafetyandEfficacyEvaluation ofImatinibMesylateinChildrenWithChronicMyeloidLeukemia(CML)PhiladelphiaChromosome-positive(Ph+)

Drug:ImatinibMesylate

Unknownstatus

Chronic MyeloidLeukemia (CML)

WithPhiladelphia

Chromosome-positive (Ph+)

Phase 2 Brazil 2011-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 63/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

AnExploratory Studyof High-doseGlivec inPatientsWithCML-CPUsingMolecularEndpoints

Drug:high-doseimatinib

Completed CML;Imatinib Phase 2 2010-08-01

A StudyInvestigating thePredictiveValue ofPhiladelphiaPositiveStem CellProperties inNewlyDiagnosed PatientsWithChronicMyeloidLeukemiainChronicPhaseReceivingTreatment WithImatinib

Procedure:Stem Celland Mutational

Assay

Unknownstatus

Chronic MyeloidLeukemia

Canada 2010-10-01

RAD001inPatientsWithChronicPhaseChronicMyeloidLeukemiaw/MolecularDisease.

Drug:RAD001;Drug:Imatinib

WithdrawnChronic Myeloid

Leukemia

Phase1/Phase

2United States 2013-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 64/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Treatment WithSecondGenerationTyrosineKinaseInhibitors(2G TKI)PostImatinibFailureSurvey

Drug:Imatinib Completed

Leukemia,Myeloid,

Chronic-Phase(CML-CP)

2010-07-01

Study ofImatinib,aPlatelet-derivedGrowthFactorReceptorInhibitor,andLBH589, aHistoneDeacetylaseInhibitor,in theTreatment ofNewlyDiagnosed andRecurrentChordoma

Drug:Imatinib +LBH589

Unknownstatus

Chordoma Phase 1 United States 2011-10-01

SafetyandEfficacyEvaluation of TwoYearImatinibTreatment inAdjuvantGastrointestinalStromalTumor(GIST)

Drug:imatinibmesylate

CompletedGastrointestinalStromal Tumors

Phase 2

Algeria;Egypt;India;Jordan;Lebanon;Russi

anFederation;Sa

udiArabia;SouthAfrica;Taiwan;Thailand;Tuni

sia;Turkey

2008-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 65/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

EfficacyofImatiniband 5-FU/Leucovorin inPatientsWithAdvancedCarcinoma of theGallbladder andBile Duct

Drug:Glivec Completed

Advanced orMetastatic

CholangiocellularCarcinoma and

Bile Duct

Phase 2 Germany 2007-04-01

Rechallenge ofImatinibin GISTHavingnoEffectiveTreatment

Drug:Imatinib;Drug:Placebo

CompletedGastrointestinalStromal Tumors

Phase 3Korea,

Republic of2010-06-01

PharmacokineticProfile ofVincristineAdministered WithImatinibfor Bcr-AblPositiveAcuteLymphoblasticLeukemia(ALL)Compared to ThatWithoutImatinibfor Bcr-AblNegativeALL

TerminatedAcute

LymphoblasticLeukemia

Canada 2010-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 66/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PilotStudy ofGleevec/ImatinibMesylate(STI-571,NSC716051)inNeurofibromatosis(NF1)PatientWithPlexiformNeurofibromas

Drug:GleevecActive, notrecruiting

Neurofibromatosis;Neurofibromas

Phase1/Phase

2United States 2012-02-01

Study toEvaluateImatinibinDesmoidTumors

Drug:Imatinib CompletedAggressive

Fibromatosis;Desmoid Tumor

Phase 2 Germany 2010-06-01

Study ofNilotinibin Ph+CML-CPPatientsWith LowImatinibTroughPlasmaConcentrations

Drug:nilotinib Terminated

CML;PhiladelphiaChromosome

Positive(Ph+);ChronicMyelogenous

LeukemiaChronic

Phase(CML-CP)Patients WithLow Imatinib

Trough Levels

Phase 4 United States 2010-10-01

Safety ofZileuton(Zyflo) inCombination WithImatinibMesylate(Gleevec)in CML.

Drug:Zileuton TerminatedChronic

MyelogenousLeukemia

Phase 1 United States 2010-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 67/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofNilotinibin AdultPatientsWithImatinibResistantor -IntolerantChronicMyeloidLeukemiain BlastCrisis,Accelerated PhaseorChronicPhase

Drug:Nilotinib CompletedChronic Myeloid

LeukemiaPhase 3

Colombia;Venezuela

2009-01-01

A StudyofImatinibWithReinductionChemotherapyUsingMitoxantrone,EtoposideandCytarabine inPatientsWithRelapsed/Refractory C-kitPositive(AML)AcuteMyeloidLeukemia

Drug:Imatinib(Gleevec)

Completed LeukemiaPhase

1/Phase2

Canada 2004-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 68/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ExtensiontoQTI571A2301 toEvaluatethe Long-termSafety,Tolerability andEfficacyofImatinibin SeverePulmonary ArterialHypertension(PAH)

Drug:Imatinib;Drug:Placebo

TerminatedPulmonary

ArterialHypertension

Phase 3

UnitedStates;Canada;Austria;Belgium;France;Germany;Italy;Japan;Korea,

Republicof;Netherlands;Spain;Switzerland;United

Kingdom

2010-04-01

Impact oftheInhibitorsofTyrosineKinase onthe MaleFertility

Drug:Imatinibtreatment

Completed

Chronic MyeloidLeukemia;Gastrointestinal Stromal

Tumors

France 2008-10-01

Effects ofcKitInhibitionbyImatinibinPatientsWithSevereRefractory Asthma(KIA)

Drug:Imatinibmesylate;Drug:Place

bo

Active, notrecruiting

Asthma Phase 2 United States 2010-11-01

PulmonaryHypertension andImatinib

Completed PAH United States 2010-03-01

SorafenibforImatinib/Sunitinib-failedGIST

Drug:Sorafenib CompletedGastrointestinalStromal Tumors

Phase 2Korea,

Republic of2009-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 69/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Trial ofTasigna(Nilotinib)400 mgTwiceDailyAlone orWithGleevec(ImatinibMesylate)400 mgDaily forPatientsWithAdvancedGastrointestinalStromalTumor(GIST)

Drug:Nilotinib;Drug:Nilotinib with

ImatinibTerminated

GIST;MetastaticDisease

Phase 2 United States 2009-02-01

StandardChemotherapyWith orWithoutNelarabine orRituximabinTreatingPatientsWithNewlyDiagnosed AcuteLymphoblasticLeukemia

Biological:palifermin;Biological:rituximab;Drug:cyclophosphamide;Drug:cytarabine;Drug:daunorubicinhydrochloride;Drug:etoposide;Drug:flud

arabinephosphate;Drug:ima

tinibmesylate;Drug:melphalan;Drug:mercaptopurine;Drug:methotrexate;Drug:nelarabine;Drug:pegasparga

se;Drug:vincristinesulfate;Procedure:all

ogeneichematopoietic stem

celltransplantation;Procedure:assessment of

therapycomplications;Radiat

ion:total-bodyirradiation

Unknownstatus

Leukemia;Mucositis;Oral

ComplicationsPhase 3

UnitedKingdom

2010-01-01

ImatinibMesylateandDocetaxelin Non-Small CellLungCancer(NSCLC)

Drug:ImatinibMesylate;Drug:Doce

taxelCompleted

Non-small CellLung Cancer

Phase 2 United States 2005-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 70/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Discontinuation ofImatinibMesylateinPatientsWithChronic-PhaseChronicMyeloidLeukemiaPreviously TreatedWithInterferon-Alpha

Other:Discontinuation of therapy

TerminatedChronic Myeloid

LeukemiaUnited States 2009-05-01

Gemcitabine andOxaliplatin (Gem-Ox) PlusGlivec inGemcitabine-refractoryPancreatic Cancer

Drug:Gemcitabine;Drug:Oxaliplatin;Drug:

ImatinibCompleted

AdvancedPancreatic

CancerPhase 1

UnitedKingdom

2006-07-01

ImatinibMesylateAndCyclophosphamideInMetronomicAdministration:DoseEscalationStudy OfImatinibMesylate

Drug:Imatinibmesylate,

Cyclophosphamide(Dosing level 1);Drug:Imatinib

mesylate,Cyclophosphamide

(Dosing level2);Drug:Imatinib

mesylate,Cyclophosphamide

(Dosing level3);Procedure:Blood

sampling

Completed Cancer Phase 1 France 2009-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 71/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofDoseEscalationVersus noDoseEscalationofImatinibinMetastaticGastrointestinalStromalTumors(GIST)Patients

Drug:Imatinibmesylate;Drug:Imati

nibmesylate;Drug:Imati

nib mesylate

TerminatedGastrointestinalStromal Tumors

Phase 3 United States 2010-01-01

Ph+/Bcr-Abl+ ALLImatinibandNilotinibRotational Study

Drug:Nilotinib;Drug:Imatinib

Active, notrecruiting

Treatment;StemCell

TransplantationPhase 2 Italy 2012-06-01

A StudyofImatinibandValproicAcid inPatientsWithChronicMyelogenousLeukemia(CML)

Drug:Gleevec(imatinib), valproic

acidWithdrawn

ChronicMyelogenous

LeukemiaPhase 2 United States 2009-09-01

Study ofGleevecandWeeklyPaclitaxelinPatientsAged 70or OlderWithAdvancedNon-small CellLungCancer

Drug:Imatinibmesylate;Drug:Paclit

axelCompleted

Non-small CellLung Cancer

Phase 2 United States 2009-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 72/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Pegaspargase andCombinationChemotherapy inTreatingPatientsWithNewlyDiagnosed AcuteLymphoblasticLeukemia

Drug:cyclophosphamide;Drug:cytarabine;Drug:dexamethasone;Drug:doxorubicinhydrochloride;Drug:i

matinibmesylate;Drug:methotrexate;Drug:methylprednisolone;Drug:pegaspargase;Drug:

vincristine sulfate

Terminated Leukemia Phase 2 United States 2009-06-01

CombinationChemotherapy inTreatingAdultPatientsWithNewlyDiagnosed AcuteLymphoblasticLeukemia

Drug:cyclophosphamide;Drug:cytarabine;Drug:dexamethasone;Drug:doxorubicinhydrochloride;Drug:

etoposidephosphate;Drug:hydrocortisone sodiumsuccinate;Drug:imati

nibmesylate;Drug:mercaptopurine;Drug:methotrexate;Drug:methylprednisolone;Drug:pegaspargase;Drug:prednisolone;Drug:prednisone;Drug:vin

cristinesulfate;Other:laborat

ory biomarkeranalysis;Radiation:ra

diation therapy

Unknownstatus

Leukemia Phase 2 2009-01-01

AutologousTransplantation forChronicMyelogenousLeukemia

Drug:Busulfan;Drug:Cyclophosphamide;

Drug:ImatinibMesylate;Procedure:

Autologous StemCell Transplantation

CompletedChronic

MyelogenousLeukemia

Phase 2 United States 2005-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 73/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Long-termSafety ofDasatinibinPatientsWithChronicMyelogenousLeukemiaorPhiladelphiaChromosomePositiveAcuteLymphoblasticLeukemia

Drug:Dasatinib;Drug:Imatinib

Completed Leukemia Phase 2

UnitedStates;Canada;Australia;Argentina;Belgium;Brazil;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Korea

, Republicof;Norway;Peru;Poland;Rus

sianFederation;So

uthAfrica;Spain;Sweden;Switzerland;Thailan

d;UnitedKingdom

2007-10-01

Treatment ofPatientsWithNephrogenicSystemicFibrosisWithGlivec

Drug:Imatinibmesylate (Glivec)

CompletedNephrogenic

Systemic FibrosisPhase 3 Denmark 2009-09-01

AnExploratory Trial toAssesstheImprovement ofAdverseEvents inChronicMyelogenousLeukemiaPatientsTreatedWithImatinibWhenSwitchedtoNilotinibTreatment

Drug:Nilotinib CompletedChronic

MyelogenousLeukemia

Phase 4United

States;Canada

2009-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 74/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Treatment of OlderAdultsWithAcuteLymphoblasticLeukemia

Drug:Prednisone;Drug:Vincristine;Drug:

Doxorubicin;Drug:PEG-

asparaginase;Drug:Cytarabine;Drug:Methotrexate;Drug:Imatinib;Drug:Clofarabine;

Drug:6Mercaptopurine

CompletedAcute

LymphoblasticLeukemia

Phase 2 United States 2009-08-01

ImatinibMesylateWith orWithoutSurgeryinTreatingPatientsWithMetastaticGastrointestinalStromalTumorThat isResponding toImatinibMesylate

Drug:imatinibmesylate;Procedure:

therapeuticconventional

surgery

TerminatedGastrointestinalStromal Tumor

Phase 3 Italy 2009-05-01

InvestigatingIntracellular andPlasmaImatinibLevels inChronicMyeloidLeukemia

CompletedChronic Myeloid

LeukemiaCanada 2009-07-01

AProspective,Multicenter Studyon BestClinicalUse ofImatinibin theAdvancedGastrointestinalStromalTumors

Drug:Imatinib CompletedAdvanced

GastrointestinalStromal Tumors

Phase 2 Italy 2002-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 75/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

GleevecandGemzarinPatientsWithEpithelialOvarianCancer

Drug:imatinibmesylate by

mouth;Drug:Gemcitabine Intravenous

Completed

OvarianCancer;Primary

PeritonealCancer

Phase 2 United States 2009-06-01

ImatinibinPatientsWithDesmoidTumorandChondrosarcoma

Drug:ImatinibMesylate

Active, notrecruiting

AdvancedDesmoid

Tumor;AdvancedChondrosarcoma

Phase 2 Italy 2007-05-01

Nilotinibin AdultPatientsWithImatinib-resistantorIntolerantChronicMyeloidLeukemiain BlastCrisis,Accelerated PhaseorChronicPhase

Drug:NilotinibApproved

formarketing

Chronic MyeloidLeukemia

Phase 3 Mexico 2008-09-01

Hydroxyurea WithorWithoutImatinibMesylateinTreatingPatientsWithRecurrentorProgressiveMeningioma

Drug:hydroxyurea;Drug:imatinib mesylate

Unknownstatus

Brain and CentralNervous System

TumorsPhase 2 Italy 2009-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 76/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Imatinib(QTI571)inPulmonary ArterialHypertension

Drug:imatinibmesylate;Drug:Place

boCompleted

PulmonaryArterial

HypertensionPhase 3

UnitedStates;Canada;Austria;Belgium;France;Germany;Italy;Japan;Korea,

Republicof;Netherlands;Spain;Sweden;Switzerlan

d;UnitedKingdom

2009-09-01

Mid-toLong-TermOutcomes inChronicMyeloidLeukemia(CML)PatientsWithCompleteCytogeneticResponseAfterImatinibas FirstLineTherapy

Other:HRQOLSurvey Packet

CompletedChronic Myeloid

LeukemiaItaly 2010-03-01

PilotStudyUsingAvastinandGleevecto TreattheProgression ofIntraluminalPulmonary VeinStenosis

Drug:Bevacizumab(Avastin) and

Imatinib Mesylate(Gleevec)

Active, notrecruiting

Pulmonary VenoOcclusiveDisease

Phase 2 United States 2008-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 77/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Pre-reinductiveDecitabine andVorinostat inRelapsedLymphoblasticLymphoma orAcuteLymphoblasticLeukemia

Drug:cytarabine;Drug:decitabine;Drug:d

oxorubicinhydrochloride;Drug:i

matinibmesylate;Drug:methotrexate;Drug:pegaspargase;Drug:prednisone;Drug:vincristin

esulfate;Drug:vorinost

at

TerminatedLeukemia;Lymph

omaPhase 2 United States 2009-04-01

Trial ofImatinib(Gleevec®) inSelectedPatientsWithMetastaticMelanoma

Drug:Imatinib(Gleevec)

CompletedMetastaticMelanoma

Phase 2 China 2008-12-01

NewIndividualizedTherapyTrial forMetastaticColorectal Cancer

Drug:Imatinibmesylate followed

by a combination ofimatinib mesylate &panitumumab;Drug:

Standard-of-caretreatment withpanitumumab

CompletedColorectal

Neoplasm;Colorectal Cancer

Phase1/Phase

2United States 2009-06-01

Five YearAdjuvantImatinibMesylate(Gleevec®) inGastrointestinalStromalTumor(GIST)

Drug:imatinibmesylate

Active, notrecruiting

GastrointestinalStromal Tumor

(GIST)Phase 2 United States 2009-07-22

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 78/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofDasatinibinPatientsWithImatinibResistantorIntolerantChronicMyeloidLeukemia

Drug:dasatinib CompletedChronic Myeloid

LeukemiaPhase 2 Japan 2009-03-01

Docetaxel(Taxotere)andImatinibMesylate(Gleevec)inHormoneRefractory ProstateCancer

Drug:Docetaxel;Drug:Imatinib Mesylate

TerminatedProstate

Cancer;ProstaticNeoplasms

Phase1/Phase

2United States 2005-05-01

IntermittentImatinibTreatment inChronicMyeloidLeukemiaandPhiladelphiaChromosome(Ph+CML)PatientsWhoAchievedaCompleteCytogeneticResponse(CCgR)onStandardImatinibTherapy

Drug:Imatinib CompletedChronic Myeloid

LeukemiaPhase 2 Italy 2008-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 79/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

TheRandomized StudyofDasatiniband High-DoseImatinib(600mg)inSuboptimalResponder

Drug:Dasatinib andImatinib

AvailableChronic Myeloid

Leukemia

Randomized StudyComparing theEffect ofDasatinibandImatinibonMalignant StemCells inChronicMyeloidLeukemia

Drug:Imatinib;Drug:Dasatinib

CompletedChronic Myeloid

LeukemiaPhase 2

Finland;Norway;Sweden

2009-03-01

Glivec inPediatricChronicMyeloidLeukemia(CML)

Drug:Imatinibmesylate 100 mg

(Glivec)Completed

Chronic MyeloidLeukemia

Phase 4 France 2004-07-01

ImatinibMesylate(Gleevec)andPaclitaxelinRecurrentPatientsofOvarianandOtherCancersofMullerianOrigin

Drug:Gleevec/Paclitaxel

Terminated Ovarian Cancer Phase 2 United States 2007-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 80/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ChartReviewStudy ofChronicMyelogenousLeukemia(CML)PatientsTreatedWithImatinibOutsideof aClinicalTrial

Other:Chart Review RecruitingChronic

MyelogenousLeukemia

United States 2005-06-01

A Phase 3Study toEvaluateEfficacyandSafety ofMasitinibinComparison toImatinibinPatientsWithGastro-IntestinalStromalTumourin FirstLineMedicalTreatment

Drug:masitinib(AB1010);Drug:imati

nib

Unknownstatus

GastrointestinalStromal Tumors

Phase 3United

States;France;Lebanon

2009-01-01

Randomized PhaseLll StudyofImatinibDoseOptimization vsNilotinibin CMLPatientsWithSuboptimalResponsetoImatinib

Drug:nilotinib;Drug:imatinib

CompletedChronic

MyelogenousLeukemia

Phase 3

Argentina;Brazil;China;Colombia;Germany;Guatemala;India;Mexico;Panama;Polan

d;RussianFederation;Ve

nezuela

2009-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 81/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

SafetyAndEfficacyStudy OfSunitinibMalate InChinesePatientsWithImatinibResistantOrIntolerantMalignantGastrointestinalStromalTumor

Drug:SunitinibMalate (SU011248)

Completed

GastrointestinalNeoplasms,

GastrointestinalStromal Tumors

Phase 4 China 2008-11-01

EfficacyofImatinibMesylateinHypereosinophilicSyndromes

Drug:Imatinib Completed

Hypereosinophilic

Syndrome;Chronic Eosinophilic

Leukemia;Chronic Idiopathic

Hypereosinophilia

Phase 2 Italy 2004-10-01

Study ofTreatment WithNilotinibin AdultPatientsWithImatinib -Resistantor -IntolerantChronicMyeloidLeukemiain BlastCrisis,Accelerated PhaseorChronicPhase

Drug:Nilotinib CompletedChronic Myeloid

LeukemiaPhase 4 Brazil 2008-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 82/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofNilotinibVersusImatinibin GISTPatients

Drug:Nilotinib(AMN107);Drug:imat

inib (STI571)Completed

GastrointestinalStromal Tumor

(GIST)Phase 3

UnitedStates;Canada;Argentina;Austria;Brazil;Bulgaria;China;Colombia;Cze

chRepublic;Denmark;Egypt;France;German

y;HongKong;Hungary;Israel;Italy;Japan;Korea,

Republicof;Mexico;Netherlands;Norway;Poland;Romania;Russi

anFederation;Singapore;Slov

akia;SouthAfrica;Spain;Sweden;Taiwan;Thailand;Turkey;United

Kingdom;Venezuela

2009-03-01

First-lineTherapyof StageIVColorectal Cancer

Drug:Oxaliplatin,Capecitabine,Bevacizumab,

Imatinib

CompletedStage IV

ColorectalCancer

Phase1/Phase

2Germany 2008-04-01

A Phase IIStudy ofDasatinibinChildrenandAdolescents WithNewlyDiagnosed ChronicPhaseCML orWith Ph+LeukemiasResistantorIntoleranttoImatinib

Drug:DasatinibActive, notrecruiting

Leukemia Phase 2

UnitedStates;Canada;Australia;Argentina;Brazil;France;Germany;India;Italy

;Korea,Republic

of;Mexico;Netherlands;Romania;Russia

nFederation;Singapore;Sout

hAfrica;Spain;U

nitedKingdom

2009-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 83/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

NilotinibandImatinibMesylateinTreatingPatientsWithEarlyChronicPhaseChronicMyelogenousLeukemia

Drug:imatinibmesylate;Drug:nilotinib;Genetic:cytogen

eticanalysis;Genetic:fluo

rescence in situhybridization;Geneti

c:microarrayanalysis;Genetic:mut

ationanalysis;Genetic:poly

merase chainreaction;Genetic:pol

ymorphismanalysis;Other:labora

tory biomarkeranalysis

Completed Leukemia Phase 2 Italy 2009-02-01

ImatinibMesylateinTreatingPatientsWith LiverMetastasis From aGastrointestinalStromalTumor

Drug:imatinibmesylate

Completed

GastrointestinalStromal

Tumor;Metastatic Cancer

Phase 2 Japan 2008-10-01

ImatinibMesylateWithVincristine andDexamethasone inAcuteLymphoblasticLeukemias WithBCR-ABLPositive

Drug:Imatinibmesylate;Drug:Interferon;Drug:Vincristin

e;Drug:Dexamethasone

Completed

Leukemia,Lymphocytic,

Acute;Philadelphia

Chromosome;Blast

Crisis;Leukemia,Myeloid, Chronic

Phase 2 France 2004-12-01

A PilotStudy ofImatinibMesylatein SteroidRefractory ChronicGraftVersusHostDisease

Drug:ImatinibUnknown

statusGraft vs Host

DiseasePhase 1 United States 2008-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 84/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

NilotinibVersusStandardImatinib(400/600mg EveryDay (QD))Comparing theKineticsofCompleteMolecularResponseforChronicMyelogenousLeukemiainChronicPhase(CML-CP)Pts WithEvidenceofPersistentLeukemiaby Real-timeQuantitativePolymerase ChainReaction(RQ-PCR)

Drug:Nilotinib;Drug:Imatinib

CompletedCHRONIC

MYELOGENOUSLEUKEMIA

Phase 3

Canada;Australia;Argentina;Brazil;France;

Spain

2009-06-01

Nilotinib800 MgAndImatinib800 MgFor TheTreatment OfPatientsWithGastrointestinalStromalTumors(Gist)Refractory ToImatinib400 Mg

Drug:Nilotinib;Drug:Imatinib

TerminatedGastrointestinalStromal Tumors

Phase 3

Canada;Argentina;Brazil;China;Korea,

Republicof;Mexico;Rus

sianFederation;Thailand;Venez

uela

2009-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 85/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Imatinib+ MTC inRelapsed/Refractory AcuteMyeloidLeukemia(AML)

Drug:Glivec;Drug:Mitoxantrone;Drug:Top

otecan;Drug:AraC

Unknownstatus

AML Phase 2 Germany 2004-07-01

Effect ofCalciumonGleevecPharmacokinetics(PK) inHealthyVolunteers

Drug:Imatinibmesylate;Dietary

Supplement:calciumcarbonate

Completed Healthy Phase 1 United States 2008-11-01

EfficacyandSafety ofAMN107inPatientsWithGastroIntestinalStromalTumors(GIST)WhoHaveFailedBothImatinibandSunitinib

Drug:AMN107 CompletedGastrointestinalStromal Tumors

Phase 2 Japan 2008-09-01

EfficacyandSafety ofNilotinibPatientsWithNewlyDiagnosed CML -CP(ChronicMyelogenousLeukemia- ChronicPhase)

Drug:Nilotinib;Drug:Imatinib

RecruitingMyelogenous

Leukemia,Chronic

Phase 3

UnitedStates;Canada;Argentina;Belgium;Brazil;Colombia;Cze

chRepublic;Denmark;Egypt;Finland;France;Germany;Italy;Japan;Poland

;RussianFederation;Singapore;Spain;Sweden;Thailand;Turkey;

UnitedKingdom

2008-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 86/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

High-DoseImatinibforRelapsed/Refractory c-KitPositiveAcuteMyelogenousLeukemia(AML)

Drug:Imatinib Completed AML Phase 2 France 2004-02-01

ImatinibMesylateto TreatSkinChangesinPatientsWithChronicGraft-Versus-HostDisease

Drug:Gleevec,STI571(Imatinib

Mesylate)Completed

Sclerotic GraftVersus Host

Disease;ImatinibMesylate

Phase 2 United States 2008-12-15

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 87/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

NilotinibandImatinibMesylateAfterDonorStem CellTransplant inTreatingPatientsWithAcuteLymphoblasticLeukemiaorChronicMyelogenousLeukemia

Drug:nilotinib;Drug:imatinib

mesylate;Other:pharmacological study

Completed

AcceleratedPhase ChronicMyelogenous

Leukemia;AdultAcute

LymphoblasticLeukemia in

Remission;BlasticPhase ChronicMyelogenous

Leukemia;Childhood Acute

LymphoblasticLeukemia in

Remission;Childhood Chronic

MyelogenousLeukemia;Chronic MyelogenousLeukemia, BCR-

ABL1Positive;ChronicPhase ChronicMyelogenous

Leukemia;Philadelphia

ChromosomePositive Adult

Precursor AcuteLymphoblastic

Leukemia;Philadelphia

ChromosomePositive

ChildhoodPrecursor AcuteLymphoblastic

Leukemia;Recurrent Adult AcuteLymphoblastic

Leukemia;Recurrent Childhood

AcuteLymphoblastic

Leukemia;Relapsing Chronic

MyelogenousLeukemia;Untreated Adult AcuteLymphoblastic

Leukemia;Untreated Childhood

AcuteLymphoblastic

Leukemia

Phase1/Phase

2United States 2008-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 88/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

StudyEvaluating IPI-504inPatientsWithGastrointestinalStromalTumors(GIST)FollowingFailure ofat LeastImatinibandSunitinib

Drug:retaspimycinhydrochloride (IPI-

504);Drug:placebo;Other:Best supportive

care

TerminatedGastrointestinalStromal Tumors

Phase 3 2008-08-01

Panobinostat(LBH589)andImatinibMesylateinTreatingPatientsWithPreviously TreatedChronicPhaseChronicMyelogenousLeukemia

Drug:imatinibmesylate;Drug:panobinostat;Genetic:pol

ymerase chainreaction;Genetic:pro

tein expressionanalysis;Genetic:wes

ternblotting;Other:flowcytometry;Other:laboratory biomarkeranalysis;Other:pharmacological study

Completed Leukemia Phase 1 United States 2008-05-01

ImatinibMesylateinTreatingPatientsWithUnresectable orMetastaticGastrointestinalStromalTumor

Drug:imatinibmesylate

Unknownstatus

GastrointestinalStromal Tumor

Phase 3 2001-01-01

GleevecinRelapsed/Refractory T CellNon-Hodgkin'sLymphoma

Drug:Imatinibmesylate

CompletedT Cell Non-

HodgkinLymphoma

Phase 2 United States 2008-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 89/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PilotStudy ofImatinibMesylateto TreatNephrogenicSystemicFibrosis

Drug:Imatinibmesylate

Unknownstatus

NephrogenicSystemic Fibrosis

Phase 2 United States 2008-05-01

Study ofMolecularResponsein AdultPatientsonNilotinibWithPhiladelphiaChromosomePositiveChronicMyelogenousLeukemia(Ph+CML) inChronicPhaseand aSuboptimalMolecularResponsetoImatinib

Drug:Nilotinib Completed

ChronicMyelogenous

Leukemia -Chronic Phase

Phase 4 United States 2008-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 90/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Phase IIStudyAiming toEvaluatetheEfficacyandSafety ofNilotinibPatientsWithGastrointestinalStromalTumors(GIST)ResistantorIntoleranttoImatiniband or to2nd LineTyrosineKinas (TK)Inhibitor

Drug:AMN107-NILOTINIB

CompletedGastrointestinalStromal Tumor

Phase 2 Israel 2008-06-01

LongTermTherapyWithImatinib:Development ofLate SideEffectsandCompliance toTreatment

Drug:Imatinib CompletedChronic MyeloidLeukemia;Newly

Diagnosed

UnitedKingdom

2008-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 91/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateandCombinationChemotherapyWith orWithout aDonorStem CellTransplant inTreatingPatientsWithNewlyDiagnosed AcuteLymphoblasticLeukemia

Drug:cytarabine;Drug:daunorubicin

hydrochloride;Drug:etoposide;Drug:imat

inibmesylate;Drug:leuco

vorincalcium;Drug:methotrexate;Drug:prednisolone;Drug:therapeu

tichydrocortisone;Drug

:vincristinesulfate;Procedure:all

ogeneichematopoietic stemcell transplantation

Completed Leukemia Phase 2Korea,

Republic of2005-10-01

Phase IIImatinib+Hydroxyurea inTreatment ofPatientsWithRecurrent/Progressive GradeII Low-GradeGlioma(LGG)

Drug:ImatinibMesylate &

HydroxyureaCompleted

Glioblastoma;Gliosarcoma

Phase 2 United States 2006-02-01

EfficacyandTolerability ofSTI571(ImatinibMesylate)for theTreatment ofFibrosis inPatientsWithSystemicSclerosis

Drug:STI571 CompletedSystemicSclerosis,

SclerodermaPhase 2

UnitedStates;Germany;Italy;Switzerland;United

Kingdom

2008-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 92/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Ph IZactima+ImatinibMesylate&Hydroxyurea forPts wRecurrentMalignant Glioma

Drug:Zactima,Gleevec,

HydroxyureaCompleted

Glioblastoma;Gliosarcoma

Phase 1 United States 2007-11-01

ImatinibandPTK787/ZK222584inRefractory and/orAdvancedSolidTumors

Drug:Imatinib andPTK/ZK222584

CompletedRefractory

Malignancy;SolidTumors

Phase 1 United States 2004-07-01

Imatinib,Capecitabine, andCisplatininTreatingPatientsWithUnresectable orMetastaticStomachCancer

Drug:capecitabine;Drug:cisplatin;Drug:im

atinib mesylateCompleted Gastric Cancer Phase 1 Germany 2007-11-01

A StudyEvaluating theEffects ofCLAGWithGleevecinRefractory orRelapsedAcuteMyeloidLeukemia

Drug:ImatinibMesylate;Drug:CLAG

Withdrawn

Chronic MyeloidLeukemia, Blast

Crisis;AcuteMyeloid

Leukemia

Phase 2 United States 2007-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 93/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofImatinibandPeginterferon α-2binGastrointestinalStromalTumor(GIST)Patients

Drug:Peginterferon-alpha 2b

(PegIFNa2b);;Drug:Imatinib

Terminated

GastrointestinalStromal

Tumors;CancerBrain;Solid

Tumors

Phase 2 United States 2007-07-01

Effect ofImatinibon BoneMetabolism inPatientsWithChronicMyelogenousLeukemiaorGastrointestinalStromalTumors

Other:blood test,urine test, and bone

density x-ray.Completed

GastricCancer;Leukemia;

ChronicMyelogenous

Leukemia

United States 2006-11-01

CompareBosutinibToImatinibInSubjectsWithNewlyDiagnosed ChronicPhasePhiladelphiaChromosomePositiveCML

Drug:Bosutinib;Drug:imatinib

CompletedChronic Myeloid

LeukemiaPhase 3

UnitedStates;Canada;Argentina;Belgium;Brazil;Chile;China;Colombia;France;Germany;H

ongKong;Hungary;India;Italy;Ja

pan;Korea,Republic

of;Latvia;Lithuania;Mexico;Poland;RussianFederation;Singapore;Sout

hAfrica;Spain;Taiwan;Thailand;Turkey;Ukra

ine;UnitedKingdom

2008-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 94/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateandSunitinibinTreatingPatientsWithGastrointestinalStromalTumors

Drug:imatinibmesylate;Drug:suniti

nibmalate;Other:pharm

acological study

TerminatedGastrointestinalStromal Tumor

Phase 1 United States 2007-07-01

ImatiniborNilotinibWithPegylatedInterferon-α2b inChronicMyeloidLeukemia

Drug:PEG-IFN-a2b WithdrawnChronic Myeloid

LeukemiaPhase 2 United States 2007-10-01

Low-DoseOralImatinibforSclerodermaPulmonaryInvolvement

Drug:ImatinibUnknown

statusSystemicSclerosis

Phase 2 Italy 2009-02-01

A Phase 2Study ofXL820 inAdultsWithAdvancedGISTResistanttoImatiniband/orSunitinib

Drug:XL820;Drug:XL820

Completed

GastrointestinalStromal

Tumors;Gastrointestinal

Neoplasms

Phase 2 United States 2007-12-01

ImatinibMesylate(Gleevec)in theTreatment ofSystemicSclerosis

Drug:ImatinibMesylate

Unknownstatus

SystemicSclerosis

Phase 2 United States 2007-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 95/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Phase IIStudy oftheAssociation ofGlivec®PlusGemzar®inPatientsWithUnresectable,Refractory,MalignantMesothelioma

Drug:Imatinibmesylate plusGemcitabine

Unknownstatus

Mesothelioma Phase 2 Italy 2008-01-01

An Open-Label,Multicenter,ExpandedAccessStudy ofOral AMN107 inAdultPatientsWithImatinib(Glivec®/Gleevec®_ -ResistantorIntolerantChronicMyeloidLeukemiain BlastCrisis,Accelerated PhaseorChronicPhase

Drug:Glivec®/Gleevec®

CompletedLeukemia,

Myeloid, Chronic2007-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 96/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

DasatinibinImatinibResistant/IntolerantChineseCML(ChronicandAdvancedPhase)Subjects

Drug:DasatinibActive, notrecruiting

Leukemia Phase 2 China 2007-11-01

NilotinibvsImatinibin AdultPatientsWithPhiladelphia (Ph+)ChronicMyelogenousLeukemiainChronicPhase(CML-CP)

Drug:Imatinib;Drug:Nilotinib (AMN107)

TerminatedMyelogenous

LeukemiaPhase 3

UnitedStates;Australia;Belgium;Br

azil;CzechRepublic;Germany;Italy;Ja

pan;Korea,Republicof;Spain

2007-10-01

Protein-TyrosineKinaseInhibitor(STI571)forTreatment ofPatientsWith Ph+ChronicMyeloidLeukemiainAccelerated andBlasticPhase

Drug:Imatinib(STI571)

CompletedChronic Myeloid

LeukemiaPhase 2 Italy 2000-08-01

ImatinibStandardDose (400mg/Day)VersusImatinibHighDose (800mg/Day)

Drug:STI571 (400mg/day; or 800

mg/day)Completed

Chronic MyeloidLeukemia

Phase 3 Italy 2004-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 97/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyUsing TheExperimental DrugCalledImatinib(Gleevec)inSubjectsWithSystemicSclerosis

Drug:Imatinib;Drug:Imatinib

CompletedAlveolitis;Systemi

c Sclerosis

Phase1/Phase

2United States 2007-08-01

Exploratory StudyofIMATINIBHighDose inIntermediate RiskChronicMyeloidLeukemiainChronicPhase

Drug:ImatinibMesilate (Glivec)

Completed

MyeloidLeukemia,Chronic,

Chronic-Phase

Phase 2 Italy 2004-01-01

GleevecStudy forPatientsWithOvarianCancer

Drug:ImatinibMesylate

Completed Ovarian Cancer Phase 2 United States 2002-03-01

Treatment ofPatientsWithEverolimus andImatinibMesylateWhoHaveProgressive GastroIntestinalStromalTumors(GIST)and AreResistanttoImatinibMesylate

Drug:Imatinibmesylate

CompletedProgressive

GastrointestinalStromal Tumor

Phase 4 Germany 2006-10-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 98/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateinTreatingPatientsWithNewlyDiagnosed AcuteMyeloidLeukemiaWhoHaveReceivedChemotherapy

Drug:imatinibmesylate;Genetic:ge

ne expressionanalysis;Genetic:mut

ationanalysis;Genetic:poly

merase chainreaction;Other:flow

cytometry;Procedure:biopsy

Active, notrecruiting

Leukemia Phase 2 United States 2008-12-01

ImatinibinSystemicSclerosis

Drug:Imatinibmesylate

CompletedScleroderma,

Systemic

Phase1/Phase

2United States 2007-07-01

Gleevec/Taxol forPatientsWithUterinePapillarySerousCarcinoma

Drug:ImatinibMesylate;Drug:Paclit

axelCompleted Uterine Cancer

Phase1/Phase

2United States 2003-12-01

Preoperative andPostoperativeImatinibMesylateStudy inPatientsWith c-KitPositiveGIST

Drug:ImatinibMesylate (Gleevec)

CompletedGastrointestinalStromal Tumors

Phase 2 United States 2003-07-01

HormonalAblation,ImatinibMesylateandDocetaxelforPatientsWithProstateCancer

Drug:Docetaxel;Drug:Imatinib

Mesylate;Drug:Leuprolide;Drug:Goserelin

Acetate

Completed Prostate Cancer Phase 2 United States 2003-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 99/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylate,Busulfan,Fludarabine, andAntithymocyteGlobulinfor CMLPatients

Drug:ImatinibMesylate;Drug:Fluda

rabine(Fludara);Drug:Busulfan;Drug:Antithymoc

yte Globulin(ATG);Drug:Tacrolimus;Drug:Methotrexate;Procedure:Donor

lymphocyte infusion(DLI);Procedure:Stem Cell Transplant

Terminated Leukemia Phase 2 United States 2003-02-01

Interleukin 11,Thrombocytopenia, ImatinibinChronicMyelogenousLeukemia(CML)Patients

Drug:Interleukin-11(IL-11 or Neumega)

Completed

Leukemia;Chronic Myelogenous

Leukemia;Chronic MyeloidLeukemia

Phase 2 United States 2005-10-01

ImatinibMesylate(Gleevec)andDocetaxelinPatientsWithHead andNeckSquamous CellCancer

Drug:ImatinibMesylate;Drug:Doce

taxelCompleted

Head and NeckCancer;Squamou

s Cell CancerPhase 2 United States 2007-01-01

ImatinibMesylate,Gemcitabine, andCapecitabine inTreatingPatientsWithAdvancedSolidTumors(Closedto Accrual12/11/2008)

Drug:capecitabine;Drug:gemcitabine

hydrochloride;Drug:imatinib

mesylate;Genetic:mutation

analysis;Genetic:nucleic acid

sequencing;Genetic:polymerase chain

reaction

Unknownstatus

UnspecifiedAdult Solid

Tumor, ProtocolSpecific

Phase 1 United States 2006-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 100/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A PhaseIII StudyofDasatinibvsImatinibinPatientsWithNewlyDiagnosed ChronicPhaseChronicMyeloidLeukemia

Drug:Dasatinib;Drug:Imatinib

CompletedMyeloid

Leukemia,Chronic

Phase 3

UnitedStates;Australia;Argentina;

Austria;Belgium;Brazil;Chile;China;Colom

bia;CzechRepublic;Denmark;France;Germany;Greece;Hungary;India;Italy;Jap

an;Korea,Republic

of;Mexico;Netherlands;Peru;Poland;Russ

ianFederation;Singapore;Spai

n;Turkey

2007-09-01

EfficacyandSafety ofImatinibinScleroderma

Drug:imatinibmesylate

CompletedScleroderma,

Localized;Scleroderma, Systemic

Phase 2 France 2007-12-01

Evaluation of thePersistence of theCompleteMolecularRemission AfterStoppingImatinibChronicMyeloidLeukemia

Behavioral:Imatinibending

CompletedMyeloid

Leukemia,Chronic

France 2007-06-01

SafetyandEfficacyofImatinibMesylateinPatientsWithPulmonary ArterialHypertension

Drug:Imatinibmesylate;Drug:Place

boCompleted

PulmonaryArterial

Hypertension

Phase2/Phase

3

UnitedStates;Austria;Germany;United Kingdom

2006-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 101/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ALL AdultConsortium Trial:Adult ALLTrial

Drug:Doxorubicin;Drug:Cytarabine;Drug:Methotrexate;Drug:

Vincristine;Drug:Cyclophosphamide;Drug:Methylprednisone;Drug:Hydrocortisone

SodiumSuccinate;Drug:Dexamethasone;Drug:6-

MP;Drug:PEG-Asparaginase;Drug:Imatinib;Drug:Etoposide;Procedure:Radiation Therapy;Drug:E.

coli Asparaginase

Active, notrecruiting

AcuteLymphoblastic

LeukemiaPhase 2

UnitedStates;Canad

a2007-04-01

A StudyofImatinibVersusNilotinibin AdultPatientsWithNewlyDiagnosedPhiladelphiaChromosomePositive(Ph+)ChronicMyelogenousLeukemiainChronicPhase(CML-CP)

Drug:nilotinib;Drug:imatinib

Active, notrecruiting

MyelogenousLeukemia,

ChronicPhase 3

UnitedStates;Canada;Argentina;Austria;Belgium;Brazil;Colombia;Czech

Republic;Denmark;Egypt;Finland;France;Germany;Hon

gKong;Hungary;Italy;Japan;K

orea,Republic

of;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Russian

Federation;Singapore;Slov

akia;SouthAfrica;Spain;Sweden;Switzerland;Taiwan;Thailand;Turk

ey;UnitedKingdom;Ven

ezuela

2007-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 102/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

EfficacyandSafety ofNilotinib(AMN107)Compared WithCurrentTreatment OptionsinPatientsWith GISTWhoHaveFailedBothImatinibandSunitinib

Drug:Nilotinib;Other:Best SupportiveCare (BSC) +/-

imatinib or sunitinib

CompletedGastrointestinalStromal Tumors

Phase 3

UnitedStates;Canada;Australia;Au

stria;CzechRepublic;France;Germany;It

aly;Korea,Republic

of;Netherlands;Poland;Spain;Switzerland

2007-03-01

ImatinibMesylateinTreatingPatientsWithStage IIIor StageIVMelanoma ThatCannotBeRemovedbySurgery

Drug:imatinibmesylate;Other:labor

atory biomarkeranalysis

Completed

Acral LentiginousMalignant

Melanoma;Recurrent

Melanoma;StageIIIA

Melanoma;StageIIIB

Melanoma;StageIIIC

Melanoma;StageIV Melanoma

Phase 2 United States 2007-04-01

ChromosomeAbnormalities inChronicMyeloidLeukemia(CML) onImatinib.GISTPatientsonImatinib

Procedure:bonemarrow aspiration

Terminated

Chronic MyeloidLeukemia;Gastrointestinal Stromal

CellTumors;Chromos

omeAbnormality

Phase 4 Canada 2005-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 103/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ChemotherapyWith orWithoutImatiniband/orPeripheral StemCellTransplant in AcuteLymphoblasticLeukemia

Drug:asparaginase;Drug:daunorubicin

hydrochloride;Drug:etoposide;Drug:idarubicin;Drug:imatinibmesylate;Drug:mercaptopurine;Drug:methotrexate;Drug:methylprednisolone;Dru

g:mitoxantronehydrochloride;Drug:prednisone;Drug:vin

cristinesulfate;Procedure:all

ogeneichematopoietic stem

celltransplantation;Proc

edure:autologoushematopoietic stem

celltransplantation;Proc

edure:peripheralblood stem cell

transplantation;Radiation:radiation

therapy

Completed Leukemia Phase 2 Italy 2004-10-01

Ph IIStudy ofPerifosinePlusGleevecforPatientsWith GIST

Drug:Perifosine;Drug:Imatinib Mesylate

CompletedGastrointestinalStromal Tumors

Phase 2 2006-08-01

Effect of aProtonPumpInhibitoronGleevec®inHealthyVolunteers

Drug:ImatinibMesylate;Drug:Ome

prazoleCompleted Healthy Phase 1 United States 2007-04-01

Registration ofChildrenWith CMLandTreatment WithImatinib

Unknownstatus

MyeloidLeukemia,

ChronicGermany 2007-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 104/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PatientsCompleting CoreProtocol(CAMN107A2103),ExhibitingStableDisease(SD),PartialResponse(PR) orCompleteResponse(CR) toNilotinibinCombination WithImatinib

Drug:Nilotinib,Imatinib

CompletedGastrointestinalStromal Tumors

Phase 1United

States;France;Italy

2006-11-01

Effects ofImatinibMesylateinPolycythemia Vera

Drug:ImatinibMesylate

CompletedPolycythemia

VeraPhase 2 2007-02-01

Effect ofImatinibMesylateand thePharmacokineticsofAcetaminophen/ParacetamolinPatientsWithNewlyDiagnosed,PreviouslyUntreatedChronicMyeloidLeukemiainChronicPhase(CML-CP)

Drug:Imatinib/Acetaminophen

CompletedChronic MyeloidLeukemia (CML)

Phase 1Korea,

Republic of2006-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 105/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

CombinedAntiinflammatoryandAngiostaticTherapyinPatientsWithHormone-refractoryProstateCancer

Drug:imatinibmesylate;Drug:Treosulfane;Drug:etoricoxib;Drug:pioglitazone;Drug:dexamethason

e

Completed Prostate Cancer Phase 2 Germany 2007-02-01

ImatinibMesylateTreatment ofPatientsWithMalignantPeripheral NerveSheathTumors

Drug:imatinibmesylate

TerminatedMalignant

Peripheral NerveSheath Tumors

Phase2/Phase

3Germany 2006-05-01

Effects ofImatinibinSubjectsWithSeasonalAllergicRhinitisand WhoAreSensitivetoTimothyGrassPollen

Drug:Imatinib CompletedSeasonal Allergic

Rhinitis

Phase1/Phase

2

UnitedKingdom

2006-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 106/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateandBevacizumab AfterFirst-LineChemotherapy andBevacizumab inTreatingPatientsWithStage IIIBor StageIV Non-Small CellLungCancer

Biological:bevacizumab;Drug:imatinib

mesylateCompleted Lung Cancer Phase 2 United States 2006-11-01

ImatinibinPatientsWithMucosalorAcral/LentiginousMelanoma

Drug:Imatinib Completed

MucosalMelanoma;Acral/

LentiginousMelanoma;Chron

ically SunDamaged

Melanomas

Phase 2 United States 2006-07-01

StudyCombiningImatinibMesylate(Gleevec)WithSorafenibinPatientsWithAndrogen-independentProstateCancer(AIPC)

Drug:Gleevec +Sorafenib

Completed Prostate Cancer Phase 1 United States 2007-01-01

Effect ofFood onBioavailability of aModifiedReleaseFormulation ofImatinib

Drug:imatinib Completed Healthy Phase 1 2006-06-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 107/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Imatinibin AdultPatientsWithMetastatic OcularMelanoma

Drug:Imatinib Terminated Melanoma Phase 2 France 2005-12-01

Effect ofFood onBioavailability ofModifiedReleaseFormulations ofImatinib

Drug:imatinib Completed Healthy Phase 1 2006-09-01

ImatinibMesylateinPatientsWithRefractoryDesmoplastic SmallRoundCellTumors

Drug:Imatinibmesilate

Completed

RefractoryDesmoplastic

Small Round CellTumors

Phase1/Phase

2Italy 2005-08-01

TALL-104andGleevecinChronicMyelogenousLeukemiaPatients

Drug:ImatinibMesylate

(IM);Drug:TALL-104cells

TerminatedChronic

MyelogenousLeukemia

Phase 2 United States 2006-12-01

Proteinase 3 PR1PeptideMixedWithMontanide ISA-51VGAdjuvantandAdministered WithGM-CSFand PEG-INTRON(R)

Biological:PeptideVaccine (PR1

Peptide);Drug:Peginterferon alfa-

2b;Drug:Imatinib;Drug:GM-CSF

Terminated Leukemia Phase 2 United States 2006-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 108/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

OralNilotinibin AdultsWithChronicMyeloidLeukemia(CML) inBlastCrisisWho AreImatinibResistantorIntolerant

Drug:nilotinibNo longeravailable

ChronicMyelogenous

LeukemiaPhase 3 Canada 2006-12-01

ImatinibMesylateandPaclitaxelinTreatingOlderPatientsWithStage IIIBor StageIV Non-Small CellLungCancer

Drug:imatinibmesylate;Drug:paclit

axelCompleted

MalignantPleural

Effusion;Recurrent Non-small Cell

LungCancer;Stage IIIB

Non-small CellLung

Cancer;Stage IVNon-small Cell

Lung Cancer

Phase 2 United States 2006-02-01

ImatinibMesylateCombined WithIntravitrealRanibizumab intheTreatment ofChoroidalNeovascularizationSecondary to Age-RelatedMacularDegeneration

Drug:ImatinibMesylate

/RanibizumabWithdrawn

ChoroidalNeovascularizati

onPhase 1 United States 2006-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 109/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Cisplatin,Pemetrexed, andImatinibMesylateinMalignantMesothelioma

Drug:Cisplatin;Drug:Imatinib

Mesylate;Drug:Pemetrexed;Drug:Dexame

thasone

Completed Mesothelioma Phase 1 United States 2006-08-01

A StudyofEverolimus inCombination WithImatinibinMetastaticMelanoma

Drug:everolimus;Drug:Imatinib

TerminatedMetastaticMelanoma

Phase 2 United States 2006-02-01

TumorTissueAnalysisinPatientsReceivingImatinibMesylateforMalignant Glioma

Drug:imatinibmesylate;Other:phar

macologicalstudy;Procedure:con

ventional surgery

CompletedBrain and CentralNervous System

TumorsUnited States 2006-07-01

Glivec®(ImatinibMesylate,STI571) inMonotherapyVersusGlivec®-InterferonAlpha intheTreatment ofChronic-PhaseChronicMyeloidLeukaemia

Drug:Glivec;Drug:Interferon

CompletedChronic Myeloid

LeukaemiaPhase 4 Spain 2003-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 110/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Imatinib,Bevacizumab, andCyclophosphamideinPatientsWithRefractoryMetastatic SolidTumors

Biological:bevacizumab;Drug:cyclophosphamide;Drug:imatini

b

CompletedUnspecifiedAdult Solid

TumorPhase 1 United States 2006-08-01

ImatinibMesylate,Vatalanib,andHydroxyurea inTreatingPatientsWithRecurrentorRelapsedMalignant Glioma

Drug:hydroxyurea;Drug:imatinib

mesylate;Drug:vatalanib

CompletedBrain and CentralNervous System

TumorsPhase 1 United States 2005-07-01

Use andTolerability ofImatinibMesylate(Gleevec)inLeukemiaPatients

Drug:ImatinibMesylate

Completed Leukemia United States 2003-08-01

STI 571(GLIVEC)in theTreatment of AdultAcuteLymphoblasticLeukemia

Drug:Imatinib CompletedAcute

LymphoblasticLeukemia

Phase 2 Italy 2001-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 111/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

SafetyAndEffectiveness OfDailyDosingWithSunitinibOrImatinibInPatientsWithGastrointestinalStromalTumors

Drug:sunitinibmalate;Drug:imatini

b mesylateTerminated

GastrointestinalStromal Tumor

Phase 3

UnitedStates;Germa

ny;HongKong;Italy;Korea, Republicof;Spain;United Kingdom

2007-06-01

EfficacyandSafety ofImatinibandVinorelbine inPatientsWithAdvancedBreastCancer

Drug:Imatinib andVinorelbine

Completed Breast Cancer Phase 4 Germany 2006-06-01

Interferonand GM-CSFCompared WithImatinibMesylateandVaccineTherapyinPatientsWithChronicPhaseCML on aTKI

Biological:GM-K562cell

vaccine;Biological:recombinantinterferon

alfa;Biological:sargramostim

Recruiting Leukemia Phase 2 United States 2006-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 112/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofDasatinibvs. High-DoseImatinib(600 mg)inPatientsWithChronicPhaseChronicMyeloidLeukemia(CML)WhoFailed toAchieveCompleteCytogeneticResponseAfter 3-18MonthsofImatinibTherapy

Drug:Dasatinib;Drug:Imatinib

Terminated Leukemia Phase 3 United States 2007-04-01

ImatinibMesylateandHydroxyurea inTreatingPatientsWithRecurrentorProgressiveMeningioma

Drug:hydroxyurea;Drug:imatinib mesylate

CompletedGlioblastoma;Gli

osarcomaPhase 2 United States 2005-05-01

ImatinibinCombination WithDacarbazine andCapecitabine inMedullaryThyroidCarcinoma

Drug:Capecitabine(Xeloda);Drug:DTIC-

Dome(Dacarbazine);Drug:

Gleevec (ImatinibMesylate)

TerminatedSolid

Tumor;ThyroidCancer

Phase1/Phase

2United States 2004-12-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 113/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateandTemozolomide inTreatingPatientsWithMalignant Glioma

Drug:imatinibmesylate;Drug:temozolomide;Other:phar

macological study

CompletedBrain and CentralNervous System

TumorsPhase 1 United States 2004-07-01

Study ofDasatinibinImatinibResistantorIntolerantSubjectsWithChronicorAdvancedPhaseCML orPhiladelphiaChromosomePositiveALL

Drug:Dasatinib Withdrawn

Chronic MyeloidLeukemia;AcuteLymphoblastic

Leukemia

Phase2/Phase

3

Hungary;Italy;Netherlands;

Poland;Russian

Federation;United

Kingdom

2006-12-01

Letrozole(Femara)PlusImatinibMesylate(Gleevec)for BreastCancerPatients

Drug:ImatinibMesylate;Drug:Letro

zole

Active, notrecruiting

Breast Cancer Phase 2 United States 2003-10-01

Study ofBMS-354825 inSubjectsWith CMLWho AreResistantto orIntolerantofImatinibor Ph+Allin Japan

Drug:Dasatinib;Drug:Dasatinib;Drug:Dasatinib;Drug:Dasatinib;Drug:Dasatinib;Drug

:Dasatinib

CompletedChronic

MyelogenousLeukemia

Phase1/Phase

2Japan 2005-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 114/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PHA-739358 inTreatingPatientsWithChronicMyelogenousLeukemiaThatRelapsedAfterImatinibMesylateor c-ABLTherapy

Drug:danusertib;Other:laboratory

biomarkeranalysis;Other:pharmacological study

Unknownstatus

Leukemia Phase 2 United States 2007-03-01

SafetyandEfficacyofImatinibVersusInterferon-α PlusCytarabine inPatientsWithNewlyDiagnosedPhiladelphiaChromosomePositiveChronicMyelogenousLeukemia

Drug:imatinibmesilate;Drug:interfe

ron-alpha (INF-a);Drug:cytarabine

(ARA-C)

CompletedChronic

MyelogenousLeukemia

Phase 3

UnitedStates;Canada;Australia;Austria;Belgium;Denmark;France;Germany;Italy;Netherla

nds;NewZealand;Norway;Spain;Sweden;Switzerl

and;UnitedKingdom

2000-06-01

Everolimus andImatinibMesylateinTreatingPatientsWithMetastatic orUnresectableKidneyCancer

Drug:Everolimus;Drug:imatinib mesylate

Completed Kidney Cancer Phase 2 United States 2006-01-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 115/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Treatment of AcuteLymphoblasticLeukemia(ALL) inYoungerAdults

Drug:Rituximab;Drug:Imatinib Mesylate

CompletedLeukemia,

LymphocyticPhase 3 France 2006-05-01

ComparingImatinibStandardDoseWithImatinibHighDoseInductioninPretreated ChronicMyeloidLeukemia(CML)PatientsinChronicPhase

Drug:ImatinibUnknown

statusChronic Myeloid

LeukemiaPhase 3 Austria 2004-01-01

ImatinibMesylateWith orWithoutBevacizumab inTreatingPatientsWithMetastatic orUnresectableGastrointestinalStromalTumor

Biological:Bevacizumab;Drug:Imatinib

Mesylate;Other:Laboratory Biomarker

Analysis;Other:Pharmacological Study

CompletedGastrointestinalStromal Tumor

Phase 3United

States;Canada

2008-04-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 116/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Phase IStudy ofDasatinib(BMS-354825)andImatinibinSubjectsWithChronicMyeloidLeukemiainChronicPhase

Drug:Dasatinib incombination with

imatinibWithdrawn

MyeloidLeukemia,Chronic,

Chronic-Phase

Phase 1 United States 2006-08-01

Gemcitabine WithorWithoutImatinibMesylateinTreatingPatientsWithMetastatic orUnresectableKidneyCancer

Drug:gemcitabinehydrochloride;Drug:i

matinibmesylate;Genetic:ge

ne expressionanalysis;Genetic:prot

ein expressionanalysis;Other:immu

nohistochemistrystaining

method;Other:laboratory biomarker

analysis

Terminated Kidney Cancer Phase 2 United States 2006-04-01

Gemcitabine andImatinibMesylateinTreatingPatientsWithRecurrentorMetastatic Non-Small CellLungCancer

Drug:gemcitabinehydrochloride;Drug:i

matinib mesylateTerminated Lung Cancer Phase 2 United States 2006-04-01

Gemcitabine +/-ImatinibMesylate,Patientsw/PreviouslyTreatedMetastatic BreastCancer

Drug:gemcitabinehydrochloride;Drug:i

matinib mesylateCompleted Breast Cancer Phase 2 United States 2006-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 117/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Study ofDasatinibinPatientsWithChronicPhaseChronicMyeloidLeukemiaand aSuboptimalResponsetoImatinib

Drug:Imatinib;Drug:Dasatinib

TerminatedLeukemia,

Myeloid, ChronicPhase 2

Belgium;Finland;France;Germany;Italy;Norway;Portugal

;RussianFederation;Spain;Sweden;U

nitedKingdom

2006-08-01

DasatinibinTreatingYoungPatientsWithRecurrentorRefractory SolidTumorsorPhiladelphiaChromosome-PositiveAcuteLymphoblasticLeukemiaorChronicMyelogenousLeukemiaThat DidNotRespondtoImatinibMesylate

Drug:dasatinib;Other:pharmacological

study;Other:laboratory biomarker

analysis

Completed

AcceleratedPhase ChronicMyelogenous

Leukemia;BlasticPhase ChronicMyelogenous

Leukemia;Childhood Chronic

MyelogenousLeukemia;Chronic MyelogenousLeukemia, BCR-

ABL1Positive;Meninge

al ChronicMyelogenous

Leukemia;Recurrent Childhood

AcuteLymphoblastic

Leukemia;Relapsing Chronic

MyelogenousLeukemia;Unspecified Childhood

Solid Tumor,Protocol Specific

Phase 1 United States 2006-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 118/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

PilotStudy ofImatinib(Gleevec)asTreatment forAdvancedThymicCarcinoma

Drug:Gleevec(imatinib)

CompletedThymic

CarcinomaPhase 1 United States 2006-04-01

ExpandedAccessProgramofAMN107inImatinib-resistantorIntolerantAdultPatientsWithChronicMyeloidLeukemia

Drug:AMN107No longeravailable

Chronic MyeloidLeukemia

Phase 3

UnitedStates;Canada;Australia;Austria;Belgium;Brazil;China;C

zechRepublic;Denmark;France;Germany;Gre

ece;HongKong;Hungary;Ireland;Italy;

Korea,Republic

of;Lebanon;Malaysia;Mexico;Netherlands;Norway;Poland;Russian

Federation;Singapore;Slov

akia;SouthAfrica;Spain;Sweden;Switzerland;Taiwan;Thailand;Turk

ey;UnitedKingdom

2006-01-01

VaccineTherapyandImatinibMesylateinTreatingPatientsWithChronicPhaseChronicMyelogenousLeukemia

Biological:GM-K562cell

vaccine;Drug:imatinib mesylate

Active, notrecruiting

Leukemia Phase 1 United States 2005-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 119/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofDasatinibinPatientsWithChronicMyelogenousLeukemiaWho AreResistantorIntolerantofImatinibMesylate

Drug:Dasatinib Completed

Leukemia,Myeloid,

Chronic;Leukemia, Lymphocytic,

Acute, L2

Phase 2United

States;Canada

2006-02-01

ImatinibVersusImatiniband Peg-InterferoninPatientsWith Ph+CML andCompleteCytogeneticResponseAfterImatinibTherapy

Drug:PegylatedInterferon and

Imatinib

Unknownstatus

Leukemia,Myeloid,

Philadelphia-Positive

Phase 3 Israel 2006-02-01

EfficacyandSafety ofImatinibMesylatePlusHydroxyurea (HU)inPatientsWithRecurrentGlioblastomaMultiforme (GBM)

Drug:Imatinibtablets;Drug:Hydrox

yurea capsulesTerminated

RecurrentGlioblastoma

Multiforme(GBM)

Phase 2 United States 2006-02-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 120/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

GleevecAdministeredPreoperatively toReduceGastrointestinalStromalTumor(GIST)

Drug:Imatinibmesylate

Unknownstatus

GastrointestinalStromal Tumors

Phase 2 Canada 2005-08-01

ImatinibMesylateinTreatingPatientsWithRecurrentorRefractoryFibromatosis

Drug:imatinibmesylate

Completed Desmoid TumorPhase

1/Phase2

France 2004-09-01

SafetyandEfficacyofImatinibAdded toChemotherapy inTreatment of Ph+AcuteLymphoblasticLeukemiainChildren

Drug:Standardchemotherapy +

ImatinibCompleted

AcuteLymphoblastic

Leukemia;Philadelphia

Chromosome

Phase 2 France 2005-12-01

ImatinibMesylateandGemcitabine inTreatingPatientsWithLocallyAdvanced,Metastatic, orRecurrentPancreatic Cancer

Drug:Gemcitabine;Drug:Imatinib

mesylateTerminated

PancreaticCancer

Phase 1 United States 2005-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 121/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

AdjuvantImatinibin High-riskGastrointestinalStromalTumor(GIST)With C-kitMutation

Drug:Imatinibmesylate (Glivec)

CompletedSarcoma;Gastrointestinal Stromal

TumorsPhase 2

Korea,Republic of

2005-04-01

ImatinibMesylate,Daunorubicin, andCytarabine inTreatingPatientsWithRelapsedAcuteMyeloidLeukemia

Drug:cytarabine;Drug:daunorubicin

hydrochloride;Drug:imatinib mesylate

Completed Leukemia Phase 1 United States 2003-07-01

SorafenibinTreatingPatientsWithMalignantGastrointestinalStromalTumorThatProgressed Duringor AfterPreviousTreatment WithImatinibMesylateandSunitinibMalate

Drug:SorafenibTosylate

Active, notrecruiting

GastrointestinalStromal Tumor

Phase 2 United States 2005-09-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 122/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

EfficacyandSafety ofOralAMN107in AdultsWithChronicMyelogenousLeukemiaResistantand/orIntoleranttoImatinibMesylateTherapy

Drug:AMN107 CompletedLeukemia,

Myeloid, Chronic

Phase2/Phase

3Israel 2006-05-01

Cladribine,Cytarabine, andImatinibMesylateinTreatingPatientsWithRefractory orRelapsedAcuteMyeloidLeukemiaor BlasticPhaseChronicMyelogenousLeukemia

Biological:filgrastim;Drug:cladribine;Drug:cytarabine;Drug:ima

tinib mesylate

Completed Leukemia Phase 1 United States 2005-03-01

ImatinibMesylateandCapecitabine inTreatingPatientsWithAdvancedSolidTumors

Drug:capecitabine;Drug:imatinib

mesylateCompleted

UnspecifiedAdult Solid

Tumor, ProtocolSpecific

Phase 1 United States 2003-08-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 123/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A StudyofImatinibandDocetaxelinProstateCancer

Drug:Gleevec;Drug:Docetaxel

Completed Prostate Cancer Phase 2 United States 2005-08-01

ImatinibMesylateAfterIrinotecanandCisplatininTreatingPatientsWithExtensive-StageSmall CellLungCancer

Drug:Cisplatin;Drug:Gleevec™;Drug:irinot

ecanCompleted Lung Cancer Phase 2 United States 2002-02-01

ImatinibMesylateinTreatingPatientsWithMyelofibrosis

Drug:imatinibmesylate

TerminatedChronic

Myeloproliferative Disorders

Phase 2 United States 2005-08-01

ImatinibMesylateAfter aDonorStem CellTransplant inTreatingPatientsWithPhiladelphiaChromosome-PositiveLeukemia

Drug:imatinibmesylate;Procedure:

adjuvant therapyCompleted Leukemia

Phase1/Phase

2United States 2004-01-01

NeoadjuvantImatinibinDermatofibrosarcomaProtuberans

Drug:imatinibmesylate

CompletedDermatofibrosar

comaProtuberans

Phase 2 United States 2006-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 124/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

A Studyof theEfficacyandSafety ofImatinibMesylateinPatientsWithUnresectable orMetastaticGastrointestinalStromalTumorsExpressing C-kitGene

Drug:Imatinibmesylate

Completed

Unresectable orMetastaticMalignant

GastrointestinalStromal Tumor

(GIST)

Phase 2United

States;Australia;Finland

2000-06-01

Phase IIClinicalStudy ofImatinibMesylateinPatientsWithMalignantGastrointestinalStromalTumors(Extension Study)

Drug:ImatinibMesylate

CompletedGastrointestinalStromal Tumors

Phase 2 2002-09-01

Efficacy,SafetyandLong-termPrognosisofImatinibinPatientsNewlyDiagnosed WithChronicMyelogenousLeukemia(ChronicPhase)

Drug:Imatinib Completed

ChronicMyelogenousLeukemia in

Chronic Phase

Phase 3 2002-11-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 125/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

SafetyandEfficacyofImatinibinCombination WithHighDoseChemotherapy forAcutePhaseChronicMyelogenousPatients

Drug:Imatinibmesylate 600

mg;Drug:Cytarabine;Drug:Daunorubicine

TerminatedChronic Myeloid

Leukemia

Phase1/Phase

2France 2001-05-01

SafetyandEfficacyofImatinibinChronicMyelogenousPatientsOlderThan 70Years

Drug:Imatinibmesylate 400 mg

CompletedChronic Myeloid

LeukemiaPhase 2 France 2002-05-01

STI571ProspectIveRandomIzed Trial:SPIRIT

Drug:Imatinibmesylate 400

mg;Drug:Imatinibmesylate 600

mg;Drug:Imatinib400 mg + Peg-

Interferon;Drug:Imatinib mesylate 400mg + Cytarabine

CompletedChronic Myeloid

LeukemiaPhase 3 France 2003-09-01

SafetyandEfficacyofImatinibinChronicMyelogenousPatientsinRelapseAfterStem CellTransplantation

Drug:Imatinibmesylate

CompletedChronic Myeloid

LeukemiaPhase 2 France 2002-05-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 126/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

ImatinibMesylateinCombination WithDocetaxelforAdvanced,Platinum-Refractory OvarianCancer

Drug:ImatinibMesylate;Drug:Doce

taxelCompleted Ovarian Cancer Phase 2 United States 2003-12-01

ImatinibMesylateandZoledronic Acid inPatientsWithChronicMyeloidLeukaemia inCytogeneticResponseWithoutMolecularResponse

Drug:Imatinibmesylate and

zoledronic acidTerminated

MyeloidLeukemia,

ChronicPhase 2 France 2005-09-01

StudyComparingImatinibWithChemotherapy asInductionin ElderlyPatientsWithPhiladelphiaPositiveAcuteLymphoblasticLeukemia(ALL)

Drug:imatinib;Drug:vincristine;Drug:cyclophosphamide;Drug:c

ytosinearabinoside;Drug:dexamethasone;Drug:idarubicin;Drug:meth

otrexate(intrathecal);Drug:Ar

aC(intrathecal);Drug:de

xamethasone(intrathecal)

Unknownstatus

PhiladelphiaPositive AcuteLymphoblastic

Leukemia;Lymphoid Blastic Phase

of ChronicMyeloid

Leukemia

Phase 2 Germany 2002-03-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 127/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

GleevecCombined WithCamptosar PlusParaplatininPreviouslyUntreatedExtensiveStageSmall CellLungCancer

Drug:Imatinib;Drug:Irinotecan;Drug:Carb

oplatinCompleted Lung Cancer Phase 2 2002-09-01

Bevacizumab,Erlotinib,andImatinibin theTreatment ofAdvancedRenal CellCarcinoma

Drug:Bevacizumab;Drug:Erlotinib;Drug:Im

atinibCompleted

Clear Cell RenalCell Carcinoma

Phase1/Phase

22004-06-01

DocetaxelPlusImatinibMesylateinMetastatic BreastCancer

Drug:Imatinib;Drug:Docetaxel

Completed Breast Cancer Phase 2 United States 2005-05-01

Study ofXelodaandGleevecinPatientsWithAdvancedSolidTumors

Drug:capecitabine,imatinib mesylate

CompletedColon

Cancer;Colorectal Cancer

Phase 1 United States 2002-12-01

Study ofImatinib(Glivec) inPatientsWithAdenoidCysticCarcinoma of theHead andNeck

Drug:ImatinibUnknown

status

Cancer of theHead and

Neck;Carcinoma,Adenoid Cystic

Phase 2 France 2004-07-01

2017/11/6 Imatinib Drug Report

https://db.yaozh.com/report/detailwap/?id=Z5mTbGpi 128/128

注册题目 干预措施 招募状态 研究疾病 研究阶段 国家 开始时间

Post-Marketing ClinicalStudy ofPostoperativeAdjuvantTherapyWithImatinibMesylateinPatientsWithGastrointestinalStromalTumors(GIST)

Drug:ImatinibMesylate

CompletedGastrointestinalStromal Tumors

Phase 4 Japan 2004-07-01

Open-label TrialofImatinibMesylateinPatientsWithUnresectableRecurrentGlioblastomaMultiformeExpressing PDGFR(PlateletDerivedGrowthFactorReceptors)

Drug:imatinibmesylate

Terminated Glioblastoma Phase 2 Brazil 2004-04-01

ImatinibMesylateinPatientsWithVariousTypes ofMalignanciesInvolvingActivatedTyrosineKinaseEnzymes

Drug:imatinibmesylate

Completed

Hypereosinophilic

Syndrome;Systemic

Mastocytosis;Chronic

MyelomonocyticLeukemia;Dermatofibrosarcoma

Phase 2 Australia 2004-09-01